[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 170
1. Mithieux F, Coriat R, De La Fouchardière C, Méeus P, Rivoire M: [Pseudo-Meigs syndrome: particular management of ovarian metastases in colorectal cancer]. Gastroenterol Clin Biol; 2008 Mar;32(3):261-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pseudo-Meigs syndrome: particular management of ovarian metastases in colorectal cancer].
  • [Transliterated title] Le pseudosyndrome de Meigs, particularité dans la prise en charge des métastases ovariennes de cancer colorectal.
  • Ascites and/or pleural effusion with ovarian metastases in colorectal cancer are usually related to peritoneal carcinomatosis.
  • Pseudo-Meigs syndrome is a characterized by non-malignant ascites and/or pleural effusion caused by pelvic tumors other than solid benign ovarian tumors.
  • We treated two patients who developed this syndrome in a context of colorectal cancer.
  • In the presence of acellular ascites with ovarian metastases from colorectal cancer, diagnosis of pseudo-Meigs syndrome may allow surgical treatment with curative intent.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Meigs Syndrome / therapy. Ovarian Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18353585.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


2. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E, Lothe RA: Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer; 2008;7:94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers.
  • BACKGROUND: Multiple epigenetic and genetic changes have been reported in colorectal tumors, but few of these have clinical impact.
  • This study aims to pinpoint epigenetic markers that can discriminate between non-malignant and malignant tissue from the large bowel, i.e. markers with diagnostic potential.
  • Possible CIMP tumors were identified by comparing the methylation profile with microsatellite instability (MSI), BRAF-, KRAS-, and TP53 mutation status.
  • RESULTS: The mean number of methylated genes per sample was 0.4 in normal colon mucosa from tumor-free individuals, 1.2 in mucosa from cancerous bowels, 2.2 in adenomas, and 3.9 in carcinomas.
  • The promoters of ADAMTS1, MAL, and MGMT were frequently methylated in benign samples as well as in malignant tumors, independent of microsatellite instability.
  • In contrast, normal mucosa samples taken from bowels without tumor were rarely methylated for the same genes.
  • CONCLUSION: Methylated ADAMTS1, MGMT, and MAL are suitable as markers for early tumor detection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. DNA Methylation. Early Detection of Cancer. Genes, Neoplasm. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenoma / genetics. Adult. Aged. Aged, 80 and over. Cluster Analysis. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Instability. Microsatellite Repeats / genetics. Middle Aged. Promoter Regions, Genetic. Sex Characteristics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9107-16 [17909015.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9 [18003927.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S7-9 [18023574.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2429-36 [18240147.001]
  • [Cites] J Transl Med. 2008;6:13 [18346269.001]
  • [Cites] J Korean Med Sci. 2008 Apr;23(2):270-7 [18437011.001]
  • [Cites] Oncol Rep. 2008 Jun;19(6):1571-6 [18497967.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1290-301 [18486467.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Dig Liver Dis. 2001 May;33(4):372-88 [11432519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):799-803 [11440966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 [11481438.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686 [18592002.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):136-42 [18542073.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):820-9 [12610180.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):479-85 [12904991.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 9;319(4):1327-33 [15194513.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):117-24 [15287024.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):407-10 [15382065.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):846-53 [15386372.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):754-9 [15386381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):475-80 [1911187.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Mol Cancer. 2004 Oct 11;3:28 [15476557.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2274-9 [16181380.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):771-8 [16207479.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2078-85 [16033773.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):924-31 [16108009.001]
  • [Cites] Genome Res. 2006 Feb;16(2):282-9 [16369045.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):593-8 [16421593.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):17-23 [16531764.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] Pathol Res Pract. 2006;202(6):415-24 [16675157.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Oncol Rep. 2006 Aug;16(2):429-35 [16820927.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Aug;21(8):1334-9 [16872319.001]
  • [Cites] Gut. 2006 Oct;55(10):1467-74 [16469793.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10664-70 [17090521.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Cell Oncol. 2006;28(5-6):259-72 [17167179.001]
  • [Cites] Hum Genet. 2007 Jan;120(5):701-11 [17024368.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):950-4 [17352030.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):273-87 [17425506.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632 [17408629.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1421-7 [17487400.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5048-55 [17785556.001]
  • (PMID = 19117505.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2639620
  •  go-up   go-down


3. Lázár G, Paszt A, Simonka Z, Rokszin R, Abrahám S: [Laparoscopic surgery in colorectal tumors]. Magy Onkol; 2010 Jun;54(2):117-22
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic surgery in colorectal tumors].
  • The minimally invasive technique, by means of the undoubted advantages of the method, has become fully accepted in the surgical treatments of the most benign and functional diseases.
  • Today it has been proven that the laparoscopic technique is safely usable also in the surgical treatment of colorectal tumors.
  • The authors, analyzing their own and the international experiences, present the laparoscopic surgical treatment of colorectal tumors.
  • Seventy-four patients were treated with laparoscopic-assisted colorectal intestinal resection in the Department of Surgery of the University of Szeged between January 1, 2005 and December 31, 2008.
  • The surgical indication was neoplastic colorectal lesion in 40 cases.
  • The histological processes of specimens justified tumor-free oral, aboral and circumferential resection in all cases.
  • Summarizing our own and international experiences it can be stated that the laparoscopic surgeries performed due to colorectal tumors are safe, and are also appropriate with respect to oncosurgery.
  • [MeSH-major] Colorectal Neoplasms / surgery. Digestive System Surgical Procedures / methods. Laparoscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colectomy / methods. Female. Humans. Hungary. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20576587.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


Advertisement
4. Mehrabi S, Akwe JA, Adams G Jr, Grizzle W, Yao X, Aikhionbare FO: Analysis of mtDNA sequence variants in colorectal adenomatous polyps. Diagn Pathol; 2010;5:66
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of mtDNA sequence variants in colorectal adenomatous polyps.
  • Colorectal tumors mostly arise from sporadic adenomatous polyps.
  • Adenomatous polyps are benign neoplasms that, by definition display some characteristics of dysplasia.
  • It has been shown that polyps were benign tumors which may undergo malignant transformation.
  • The ability to differentially diagnose these colorectal adenomatous polyps is important for therapeutic intervention.
  • Using high resolution restriction endonucleases and PCR-based sequencing, fifty-seven primary fresh frozen tissues of adenomatous polyps (37 tumors and 20 matched surrounding normal tissues) obtained from the southern regional Cooperative Human Tissue Network (CHTN) and Grady Memorial Hospital at Atlanta were screened with three mtDNA regional primer pairs that spanned 5.9 kbp.
  • [MeSH-major] Adenomatous Polyps / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA, Mitochondrial / analysis. Genetic Variation

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1460-5 [15489649.001]
  • [Cites] Science. 1987 Oct 9;238(4824):193-7 [2889267.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Gastroenterology. 1990 Feb;98(2):371-9 [2403953.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11164-8 [1454794.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):514-9 [9012815.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:30 [15482594.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1655-63 [15753359.001]
  • [Cites] Br J Cancer. 2005 Aug 8;93(3):331-7 [15956973.001]
  • [Cites] Science. 2008 May 2;320(5876):661-4 [18388260.001]
  • [Cites] Diagn Mol Pathol. 2008 Jun;17(2):94-100 [18382370.001]
  • [Cites] Carcinogenesis. 2010 Feb;31(2):296-301 [19945968.001]
  • [Cites] Hum Pathol. 2002 Mar;33(3):372-5 [11979380.001]
  • (PMID = 20929553.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / R25 GM058268
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  • [Other-IDs] NLM/ PMC2959018
  •  go-up   go-down


5. Galitskiĭ MV, Khomeriki SG, Nikiforov PA: [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy]. Eksp Klin Gastroenterol; 2009;(5):28-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy].
  • The cholecystectomy results in change of cholic acids flow into intestine.
  • Permanent type of the bile flow provokes the increase of proliferation of colic epithelial cells and increases the risk for development of right-sided colorectal tumors.
  • Meanwhile morphological features of colorectal tumors at the patients with cholecystectomy are still remaining to be clarified.
  • The goal of the study was to investigate immunohistochemical markers of proliferation and apoptosis in colorectal adenomas and adenocarcinomas at the patients with cholecystectomy.
  • 83 tumors and 49 samples of mucosa were immunostained with monoclonal mouse anti-human p53 protein (Dako) and monoclonal mouse anti-human Ki-67 antigen (Novocastra).
  • Thus, in benign colorectal tumors at the patients with retained function of gallbladder intensifying of epithelial cells proliferation is not accompanied with intensifying of apoptosis, and in malignant tumors a complete supression of apoptosis is observed.
  • The retaining of apoptosis in colorectal tumors compensates intensive proliferative activity with expectation of better prognosis.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / biosynthesis. Cell Proliferation. Cholecystectomy. Colon / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Intestinal Mucosa / metabolism. Ki-67 Antigen / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205327.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


6. Ma TL, Ni PH, Zhong J, Tan JH, Qiao MM, Jiang SH: Low expression of XIAP-associated factor 1 in human colorectal cancers. Chin J Dig Dis; 2005;6(1):10-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low expression of XIAP-associated factor 1 in human colorectal cancers.
  • The aims of the present study were: (i) to investigate the expression of XAF1 in human colorectal cancers (CRC) both in vitro and in vivo, and (ii) to evaluate the possibility of XAF1 as a new tumor marker.
  • The expression of XAF1 in tissue was relatively lower in primary CRC compared with a relatively higher level in benign colorectal tumors (P < 0.01).
  • Although the XAF1 expression in circulation of those with CRC was also lower than in those with benign tumors, there was no statistical significance (P > 0.05).
  • CONCLUSIONS: The present results suggest that the low expression of XAF1 in tumor tissue coincides with a similar level in the peripheral circulation, which contributes at least part to the malignant behavior of CRC.
  • Integrating the XAF1 relative expression value with the other three traditional tumor biomarkers created a four-parameter assay that significantly improved the rate of diagnosis of CRC.
  • [MeSH-major] Biomarkers, Tumor / blood. Colonic Neoplasms / genetics. Colonic Neoplasms / physiopathology. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Aged. Apoptosis. Case-Control Studies. Female. Gene Expression Profiling. Humans. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Zinc Fingers

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667552.001).
  • [ISSN] 1443-9611
  • [Journal-full-title] Chinese journal of digestive diseases
  • [ISO-abbreviation] Chin J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / XAF1 protein, human
  •  go-up   go-down


7. Hauenschild L, Bader FG, Laubert T, Czymek R, Hildebrand P, Roblick UJ, Bruch HP, Mirow L: Laparoscopic colorectal resection for benign polyps not suitable for endoscopic polypectomy. Int J Colorectal Dis; 2009 Jul;24(7):755-9
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colorectal resection for benign polyps not suitable for endoscopic polypectomy.
  • BACKGROUND AND AIMS: Endoscopic polypectomy still remains the cornerstone of therapy for colorectal polyps and adenomas.
  • However, if colorectal polyps are too large or not accessible for endoscopic ablation or cannot be removed without an increased risk for perforation, operative procedures are required.
  • In patients which could not be treated by endoscopic polypectomy due to size, location, and/or risk of complications, a laparoscopic colorectal resection was performed.
  • All data were prospectively assessed in our "colorectal resection" database.
  • RESULTS: The database analysis revealed 58 patients with endoscopically not resectable colorectal polyps who underwent a laparoscopic colorectal resection (intend to treat).
  • The histopathological work-up revealed benign disease in all cases.
  • CONCLUSION: Laparoscopic resection of colorectal polyps is a safe and minimally invasive technique for the management of benign colorectal tumors.
  • [MeSH-major] Colonic Polyps / pathology. Colonic Polyps / surgery. Colorectal Surgery. Endoscopy. Laparoscopy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2007 Oct;246(4):655-62; discussion 662-4 [17893502.001]
  • [Cites] Arch Surg. 2004 Jan;139(1):39-42 [14718273.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Chirurg. 2003 Oct;74(10):966-80; quiz 981-2 [15017996.001]
  • [Cites] Rev Esp Enferm Dig. 2004 May;96(5):315-21 [15180443.001]
  • [Cites] J Gastrointest Surg. 2009 Feb;13(2):275-81 [18941844.001]
  • [Cites] World J Surg. 2002 Mar;26(3):377-83 [11865378.001]
  • [Cites] Surg Endosc. 1997 Jun;11(6):643-4 [9171124.001]
  • [Cites] Surg Endosc. 2003 Sep;17(9):1461-3 [12739115.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1380-3 [14530679.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):34-41 [16012932.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3061-8 [17634484.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s243-7 [15666099.001]
  • [Cites] Cancer. 1989 Nov 1;64(9):1937-47 [2477139.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s283-90 [15666108.001]
  • [Cites] Br J Surg. 1993 Jun;80(6):788-93 [8330178.001]
  • [Cites] Surg Endosc. 1997 Feb;11(2):119-22 [9069140.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1246-9 [11005491.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):746-8 [11357040.001]
  • [Cites] Ann Surg. 2008 Jul;248(1):1-7 [18580199.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s291-4 [15666109.001]
  • [Cites] Onkologie. 2001 Feb;24(1):29-32 [11441277.001]
  • [Cites] Mayo Clin Proc. 2000 Apr;75(4):344-8 [10761487.001]
  • [Cites] Dig Dis. 2005;23(2):127-34 [16352892.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):234-41 [15278051.001]
  • [Cites] Surg Endosc. 2001 Feb;15(2):116-20 [11285950.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • (PMID = 19283390.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Kline RC, Bazzett-Matabele LB: Adnexal masses and malignancies of importance to the colorectal surgeon. Clin Colon Rectal Surg; 2010 Jun;23(2):63-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adnexal masses and malignancies of importance to the colorectal surgeon.
  • In this article, the authors review both benign and malignant ovarian masses, as the colorectal surgeon who encounters an adnexal mass at the time of surgery should be aware of the steps necessary for surgical staging and optimal tumor resection.Ovarian tumors-most of which are benign-are divided into three major categories, in order of frequency: epithelial, germ cell, and sex cord-stromal tumors.
  • Nonneoplastic conditions of the ovary that may present as adnexal masses include the following, according to World Health Organization (WHO) classification: pregnancy luteoma, hyperplasia of ovarian stroma, hyperthecosis, massive edema, solitary follicle cysts and corpus luteal cysts, multiple follicle cysts, and endometriosis.Epithelial ovarian tumors arise from the surface epithelium and can be benign or malignant.
  • Germ cell tumors are more likely to appear in females under 20 years, accounting for 70% of ovarian tumors in this age group.
  • Teratomas are the most common germ cell tumors.
  • Malignancies, in addition to malignant teratomas, include dysgerminomas, endodermal sinus tumors, and embryonal carcinomas.
  • The more common sex cord-stromal tumors include granulosa stromal cell tumors, Sertoli-Leydig cell tumors, and gynandroblastomas.Surgical staging and optimal tumor resection are also addressed, with a focus on epithelial malignancies, as they are the most relevant to colorectal surgeons.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):77-81 [11277654.001]
  • [Cites] JAMA. 1983 Dec 9;250(22):3072-6 [6358558.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):30-5 [16021055.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):185-91 [16216320.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):383-90 [17005244.001]
  • [Cites] Obstet Gynecol. 2009 Apr;113(4):775-82 [19305319.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(4):343-51 [2246093.001]
  • [Cites] Curr Top Pathol. 1989;78:85-109 [2651026.001]
  • [Cites] Environ Health Perspect. 1987 Aug;73:15-25 [3665859.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):139-44 [2680797.001]
  • [Cites] Obstet Gynecol. 1989 Dec;74(6):921-6 [2685680.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):983-9 [3373267.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):34-7 [12079297.001]
  • (PMID = 21629623.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2967325
  • [Keywords] NOTNLM ; Adnexal masses / ovarian cancer / ovarian cysts
  •  go-up   go-down


9. Brozovich M, Read TE, Salgado J, Akbari RP, McCormick JT, Caushaj PF: Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution. Surg Endosc; 2008 Feb;22(2):506-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution.
  • PURPOSE: Endoscopically unresectable apparently benign colorectal polyps are considered by some surgeons as ideal for their early laparoscopic colectomy experience.
  • (1) a substantial fraction of patients undergoing laparoscopic colectomy for apparently benign colorectal neoplasia will have adenocarcinoma on final pathology; and (2) in our practice, we perform an adequate laparoscopic oncological resection for apparently benign polyps as evidenced by margin status and nodal retrieval.
  • METHODS: Data from a consecutive series of patients undergoing laparoscopic colectomy (on an intention-to-treat basis) for endoscopically unresectable neoplasms with benign preoperative histology were retrieved from a prospective database and supplemented by chart review.
  • The median nodal harvest was 12 and all resection margins were free of neoplasm.
  • Mean diameter of benign tumors was 3.2 cm (range 0.5-10.0cm) versus 3.9cm (range 1.5-7.5cm) for adenocarcinomas (p = 0.189, t - test).
  • CONCLUSION: A substantial fraction of endoscopically unresectable colorectal neoplasms with benign histology on initial biopsy will harbor invasive adenocarcinoma, some of advanced stage.
  • This finding supports the practice of performing oncological resection for all patients with endoscopically unresectable neoplasms of the colorectum.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Am J Surg. 1999 May;177(5):384-7 [10365875.001]
  • [Cites] Ann Surg. 1979 Dec;190(6):679-83 [518167.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] AORN J. 1992 Dec;56(6):1068-73 [1463326.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):879-82 [16598402.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • (PMID = 17704872.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Skalicky T, Treska V, Liska V, Sutnar A, Molacek J, Mirka H, Ferda J, Ohlidalova K: The rare benign liver tumors. Bratisl Lek Listy; 2007;108(4-5):229-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The rare benign liver tumors.
  • As opposed to malignant secondary tumors, metastases of the colorectal carcinoma are benign tumors of the liver that are quite rare in the Czech Republic.
  • From the 55 patients operated on since 2000 at our department for benign liver tumors, the most frequent are haemangiomas, focal nodular hyperplasia (FNH) and hepatocelular adenoma.
  • Only 7.3% of them form a different histological type of a tumor than this most frequently occurring trio of tumors.
  • The authors describe three cases of rather rare liver tumors with benign behavior that have the potential of becoming malignant.
  • It concerns mucin producing biliary tumors, which correspond to the pancreatic intraductal papillary mucin tumor, hepatic cystadenoma with ovarian stroma and a liver hamartoma in an adult patient (Ref 13).
  • [MeSH-major] Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Cholangitis, Sclerosing / diagnosis. Cholangitis, Sclerosing / surgery. Cystadenoma / diagnosis. Cystadenoma / surgery. Female. Hemangioma, Cavernous / diagnosis. Hemangioma, Cavernous / surgery. Humans. Middle Aged. Pancreatic Ducts. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17694811.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  •  go-up   go-down


11. Lewin MR, Dilworth HP, Abu Alfa AK, Epstein JI, Montgomery E: Mucosal benign epithelioid nerve sheath tumors. Am J Surg Pathol; 2005 Oct;29(10):1310-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal benign epithelioid nerve sheath tumors.
  • Mucosal nerve sheath tumors have been well described in the gastrointestinal tract and other mucosal sites.
  • In a series of mucosal biopsies, we have encountered a distinct subset of mucosal peripheral nerve sheath tumors characterized by small epithelioid cells and a benign clinical course.
  • Such epithelioid nerve sheath tumors have been observed as a component of a larger study of colorectal "schwannomas," but herein we describe them in detail.
  • A series of 7 of these lesions detected on mucosal biopsies (6 colonic, 1 bladder) was received by a single large institution in consultation material.
  • Mucosal epithelioid nerve sheath tumors are a rare entity characterized by prominent epithelioid round to oval cells with an infiltrative growth pattern.
  • These lesions are often discovered incidentally and have a benign clinical course.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Intestinal Mucosa / pathology. Nerve Sheath Neoplasms / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160473.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Kume K, Murata I, Yoshikawa I, Yamasaki M, Kanda K, Otsuki M: Endoscopic piecemeal mucosal resection of large colorectal tumors. Hepatogastroenterology; 2005 Mar-Apr;52(62):429-32
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic piecemeal mucosal resection of large colorectal tumors.
  • BACKGROUND/AIMS: Since endoscopic en bloc resection of large and sessile tumors is technically difficult, endoscopic en bloc piecemeal mucosal resection (EPMR) is usually chosen for resection of such tumors.
  • Tumors resected by EPMR are, however, difficult to evaluate histologically.
  • METHODOLOGY: We removed 30 large colorectal tumors in 30 patients by EPMR between 1992-2000.
  • Patients in whom no residual tumor was found by both endoscopic and histologic examination were considered to be "cured".
  • RESULTS: Histological examination of the resected tumor tissues revealed malignancy in 43.3% (13/30).
  • Three patients had invasive malignant tumors and underwent surgery.
  • Following complete endoscopic resection, recurrences were observed in 2 patients with benign tumors, which were resected by additional endoscopic resection.
  • All patients including the two with non-invasive malignant tumors remain free from recurrence during a mean follow-up period of 45.2 months (range, 3-104 months).
  • CONCLUSIONS: EPMR of benign or non-invasive large malignant tumors is a safe and effective procedure.
  • Complete excision of large, sessile and non-invasive tumors is possible, although complete removal by EPMR cannot be verified histologically.
  • [MeSH-major] Adenoma / surgery. Carcinoma / surgery. Colorectal Neoplasms / surgery. Endoscopy, Digestive System / methods. Intestinal Mucosa / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonoscopy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816450.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


13. Cserni G, Bori R, Sejben I: Vascular invasion demonstrated by elastic stain-a common phenomenon in benign granular cell tumors. Virchows Arch; 2009 Feb;454(2):211-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular invasion demonstrated by elastic stain-a common phenomenon in benign granular cell tumors.
  • Granular cell tumor is generally benign, but rare malignant cases have been documented.
  • Features of malignancy include necrosis, cellular spindling, vesicular nuclei with large nucleoli, increased mitotic activity, high nuclear to cytoplasmic ratio, and pleomorphism, but not vascular invasion.
  • Venous invasion was incidentally identified with the orcein elastic stain in an otherwise benign granular cell tumor (propositus case).
  • Four further benign granular cell tumors were also analyzed; venous invasion was discovered in three.
  • It is suggested that vascular invasion is not uncommon in granular cell tumors and should not lead to the classification of the tumor as malignant or atypical.
  • It is also suggested that some cases of vascular invasion identified by elastic stains in tumors such as colorectal carcinomas (where these stains are recommended for routine use) may also represent invasion of vascular structures without the propensity of metastasis.
  • [MeSH-major] Blood Vessels / pathology. Elastic Tissue / pathology. Granular Cell Tumor / pathology. Staining and Labeling / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2007 Nov;50(11):1867-72 [17665249.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):291-8 [15791574.001]
  • [Cites] Histopathology. 2006 Nov;49(5):487-92 [17064294.001]
  • [Cites] Minerva Stomatol. 2006 Jul-Aug;55(7-8):423-30 [17041542.001]
  • [Cites] Arch Pathol Lab Med. 2005 Nov;129(11):1465-9 [16253028.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2313-7 [8941000.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):560-5 [18300797.001]
  • [Cites] J Pathol. 1976 Jan;118(1):9-16 [1255302.001]
  • [Cites] Histopathology. 2006 Aug;49(2):107-20 [16879388.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):769-72 [15220375.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):779-94 [9669341.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):208-11 [8119722.001]
  • [Cites] Adv Anat Pathol. 1999 Jul;6(4):186-203 [10410172.001]
  • [Cites] Am J Clin Pathol. 1985 Apr;83(4):426-30 [3984936.001]
  • [Cites] Am J Surg Pathol. 1985 Feb;9(2):125-8 [3919599.001]
  • [Cites] AJR Am J Roentgenol. 1999 Nov;173(5):1303-13 [10541110.001]
  • (PMID = 19066954.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Calistri D, Rengucci C, Casadei-Gardini A, Scarpi E, Zoli W, Falcini F, Milandri C, Amadori D, Silvestrini R: FL-DNA approach for noninvasive early diagnosis of colorectal cancer in FOBT-screened patients. J Clin Oncol; 2009 May 20;27(15_suppl):11062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FL-DNA approach for noninvasive early diagnosis of colorectal cancer in FOBT-screened patients.
  • : 11062 Background: A promising approach for the early diagnosis of colorectal cancer (CRC) is the evaluation of genomic DNA integrity (FL-DNA) extracted from stool.
  • Pilot and confirmatory studies carried out by our group have shown that, thanks to its diagnostic accuracy, this molecular assay could be a useful tool for the non-invasive, early diagnosis of CRC.
  • More than one third (216) of the group had only benign disease (hemorrhoids, diverticulitis, inflammation, etc), hyperplastic polyps or nothing.
  • RESULTS: Using a cut-off of 10 ng, the molecular analysis detected over 90% of the colorectal cancers and about 50% of the high- and low-grade adenomas.
  • The test also confirmed its capacity to identify colorectal cancer in asymptomatic individuals.
  • A more in depth DNA stool evaluation in negative FOBT individuals could reveal the test's usefulness in unmasking colorectal tumors and adenomas missed by FOBT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963138.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Gundrum JD, Go R, Kwong R: Cancer in the oldest old population in the United States: Current statistics and projections. J Clin Oncol; 2009 May 20;27(15_suppl):9553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We included patients who had a previous cancer before age 85, but excluded benign tumors, myeloproliferative, and myelodysplastic neoplasms.
  • The 10 leading cancers by incidence (both sexes and decreasing order) are colorectal (388.9), lung (287.7), breast (250), prostate (211.5), urinary bladder (162.5), non-Hodgkin lymphoma (110.9), leukemia (85.1), melanoma (65), renal (46.4), and uterine (40.2).
  • The incidences of melanoma, non-Hodgkin lymphoma, renal, and lung cancers are increasing, while those of leukemia, prostate, breast, and colorectal cancers are decreasing.
  • The top 5 causes of cancer deaths are lung and bronchus (21%), colorectal (15%), pancreatic (7.1%), prostate (5.9%), and breast cancers (5.3%).
  • Cancer specific survival (CSS) has been increasing continuously since 1973 for melanoma, non-Hodgkin lymphoma, breast, colorectal, prostate, and urinary bladder cancers but decreasing in recent years for colorectal, breast, prostate, and uterine cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963637.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Marginean EC, Torlakovic G, Neufeld H, Torlakovic E: Association of upregulated GATA-4 transcription factor colorectal adenocarcinoma with metastatic and primary tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15093

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of upregulated GATA-4 transcription factor colorectal adenocarcinoma with metastatic and primary tumors.
  • Nuclear factor-B (NF-B) activation was shown to promote the growth of the colon tumors in experimental models and was correlated with tumor angiogenesis and progression in human colorectal cancer.
  • METHODS: Forty cases of colorectal adenocarcinoma were evaluated.
  • The benign colonic mucosa and the matching metastatic tumors of the same patients were also included in the study.
  • RESULTS: GATA-4 was expressed in 32% of colorectal adenocarcinoma, but not in benign colonic mucosa (p=0.0001, Chi-Square).
  • GATA-4 was also significantly more expressed in metastatic (41%) than in primary (21%) colorectal adenocarcinoma (p<0.0001, Chi-Square).
  • NF-B activation was not present in any of the samples of benign colonic mucosa, but it was detected in 64% adenocarcinomas (p<0.0001, Chi-Square).
  • CONCLUSIONS: GATA-4, a developmental transcription factor is not expressed by normal colonic mucosa, but is present in 1/5 of primary tumors that gave rise to distant metastases and in almost 1/2 of their respective metastases.
  • GATA-4 may have a role in colorectal adenocarcinoma development and progression and it should be further evaluated in prospective studies as a putative adverse prognostic factor in colorectal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964606.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Torlakovic E, Marginean EC, Torlakovic G, Geyer R, Neufeld H, Decoteau J: Downregulation of RIZ1 protein expression in left-sided versus right-sided primary colorectal carcinomas and their distant metastases and the association with NF-B activation. J Clin Oncol; 2009 May 20;27(15_suppl):e15112

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of RIZ1 protein expression in left-sided versus right-sided primary colorectal carcinomas and their distant metastases and the association with NF-B activation.
  • RIZ1 frameshift mutations were recently reported to be confined to MSI-H colorectal tumors and proximal tumor origin, while its hypermethylation was not limited to MSI-H tumors.
  • However, RIZ1 protein expression has not been evaluated in colorectal carcinoma.
  • METHODS: TMAs included 28 left-sided and 12 right-sided primary colorectal adenocarcinomas, their matched normal mucosa and their respective distant metastases.
  • Left-sided tumors were compared to right-sided tumors for expression of RIZ1 protein and NF- B activation.
  • NF- B activation was determined by IHC detecting nuclear translocation of its p65 subunit in more than 30% tumor nuclei.
  • RESULTS: RIZ1 was less expressed in tumors than in benign mucosa (p<0.0001, r=- 0.377, Chi-Square).
  • Left-sided primary tumors showed less RIZ1 protein expression than right-sided (p=0.03, Chi-Square).
  • NF- B activation was more frequent in left-sided primary tumors and their respective metastases (35% in right vs. 67% in left; p=0.002, Chi-Square Test).
  • RIZ1 expression and NF- B activation were almost identical in primary and their respective metastatic tumors with only 3 discrepant results for NF- B status and 2 discrepant results in RIZ1 expression.
  • CONCLUSIONS: While RIZ1 downregulation in colorectal adenocarcinoma due to RIZ1 mutations appears to be associated with MSI-H and proximal origin, its protein expression appears to be downregulated more often in distal tumors.
  • NF- B activation is strongly associated with lower RIZ1 protein expression in colorectal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960861.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Königsrainer I, Steurer W, Witte M, Königsrainer A: Liver resection without hilus preparation and with selective intrahepatic hilus stapling for benign tumors and liver metastasis. Langenbecks Arch Surg; 2007 Jul;392(4):485-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection without hilus preparation and with selective intrahepatic hilus stapling for benign tumors and liver metastasis.
  • Extrahepatic isolation of portal vein, hepatic artery and hepatic duct, as well as lymphadenectomy of the liver hilum are generally accepted steps of liver resection, even for metastatic and benign indications.
  • MATERIALS AND METHODS: Thirty-eight consecutive patients with resection for metastases and benign liver tumors were selected.
  • To date, no tumor recurrence was found in the hilum during the follow-up period.
  • Hilar dissection can, thus, be avoided in liver metastasis and benign liver tumors.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery. Surgical Stapling
  • [MeSH-minor] Aged. Colorectal Neoplasms / pathology. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1999 Oct;42(10):1285-90; discussion 1290-1 [10528765.001]
  • [Cites] J Surg Oncol. 2005 Apr 1;90(1):43-5 [15786414.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):137-8; author reply 138 [16371749.001]
  • [Cites] Ann Surg. 2005 Apr;241(4):582-90 [15798459.001]
  • [Cites] Br J Surg. 2006 Jun;93(6):685-9 [16703653.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):286-91 [9880776.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):202-9 [14745328.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):260-4 [16858189.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):111-9 [12832973.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):397-406; discussion 406-7 [12368667.001]
  • [Cites] World J Surg. 1995 Sep-Oct;19(5):764-7 [7571678.001]
  • [Cites] Ann Surg. 2001 Jan;233(1):45-50 [11141224.001]
  • [Cites] Ann Surg. 1996 Aug;224(2):155-61 [8757378.001]
  • [Cites] Ann Surg. 1997 Dec;226(6):704-11; discussion 711-3 [9409569.001]
  • [Cites] World J Gastroenterol. 2006 Feb 14;12(6):935-9 [16521223.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):942-5 [8813780.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):121-4 [8653335.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):210-5 [10024102.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):814-22, discussion 822-3 [16327491.001]
  • (PMID = 17530278.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Achiam MP, Andersen LP, Klein M, Løgager V, Chabanova E, Thomsen HS, Rosenberg J: Differentiation between benign and malignant colon tumors using fast dynamic gadolinium-enhanced MR colonography; a feasibility study. Eur J Radiol; 2010 Jun;74(3):e45-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between benign and malignant colon tumors using fast dynamic gadolinium-enhanced MR colonography; a feasibility study.
  • BACKGROUND: Colorectal cancer will present itself as a bowel obstruction in 16-23% of all cases.
  • However, not all obstructing tumors are malignant and the differentiation between a benign and a malignant tumor can be difficult.
  • The purpose of our study was to determine whether fast dynamic gadolinium-enhanced MR imaging combined with MR colonography could be used to differentiate a benign from a malignant obstructing colon tumor.
  • METHODS: Patients with benign colon tumor stenosis, based on diverticulitis, were asked to participate in the study.
  • The same number of patients with verified colorectal cancer was included.
  • Two blinded observers analyzed the tumors on MR by placing a region of interest in the tumor and a series of parameters were evaluated, e.g. wash-in, wash-out and time-to-peak.
  • The wash-in and wash-out rates were significantly different between the benign and malignant tumors, and a clear distinction between benign and malignant disease was therefore possible by looking only at the MR data.
  • CONCLUSION: The results showed the feasibility of using fast dynamic gadolinium-enhanced MR imaging to differentiate between benign and malignant colonic tumors.
  • With a high intra-class correlation and significant differences found on independent segments of the tumor, the method appears to be reproducible.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Diverticulitis / diagnosis. Diverticulitis / etiology. Image Enhancement / methods. Magnetic Resonance Imaging / methods. Meglumine. Organometallic Compounds
  • [MeSH-minor] Adult. Aged. Contrast Media. Diagnosis, Differential. Feasibility Studies. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Single-Blind Method

  • MedlinePlus Health Information. consumer health - Diverticulosis and Diverticulitis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19419830.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00114829
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 0 / gadoterate meglumine; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


20. Huguet KL, Metzger PP, Menke DM: Colorectal lymphangioma. Am Surg; 2007 Apr;73(4):414-6
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal lymphangioma.
  • Lymphangiomas of the colon are historically rare benign tumors.
  • [MeSH-major] Cecal Neoplasms / diagnosis. Colonoscopy. Lymphangioma / diagnosis

  • Genetic Alliance. consumer health - Lymphangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17439042.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Gao Y, Zhang B: [Expression of TEIF protein in colorectal tumors and its correlation with centrosome abnormality]. Ai Zheng; 2009 Dec;28(12):1277-82
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of TEIF protein in colorectal tumors and its correlation with centrosome abnormality].
  • BACKGROUND AND OBJECTIVE: Telomerase transcriptional elements-interacting factor (TEIF) gene found recently by our research group is a transcription factor of a kind of human telomerase reverse transcriptase (hTERT) gene, and expresses in many kinds of tumor tissues.
  • This study was to evaluate the expression of TEIF protein in human colorectal tumors and to explore its correlation with centrosome abnormality.
  • METHODS: The expression of TEIF in 10 specimens of normal intestinal mucosa tissue, 30 specimens of colorectal cancer, and 54 specimens of colorectal adenoma was detected by immunohistochemistry.
  • RESULTS: Immunohistochemistry results showed that the differences of TEIF protein expression between the normal group and each tumor groups were statistically significant (P<0.01), and the difference of TEIF protein expression between the malignant tumor group and the benign group was not significant (P>0.05).
  • Immunofluorescence results showed that centrosome amplification-positive rate was significantly higher in the colorectal cancer group than in the normal group or the adenoma group (both P<0.01); the difference of the centrosome amplification positive rate between Grade I adenoma and Grade III adenoma was statistically significant (P<0.05), and the differences of the centrosome amplification positive rate between Grade II adenoma and Grade I or III adenoma were statistically significant (P>0.05).
  • CONCLUSIONS: TEIF protein and centrosome amplification is commonly found in colorectal tumors.
  • The expression level of TEIF is related to tumor histological grade and malignant degree.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Centrosome / pathology. Colorectal Neoplasms / metabolism. Transcription Factors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958622.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Transcription Factors; 0 / Tubulin; EC 2.7.1.- / SCYL1 protein, human
  •  go-up   go-down


22. Belizon A, Balik E, Horst PK, Shantha Kumara HM, Nasar A, Whelan RL: Platelet-derived growth factor (subtype BB) is elevated in patients with colorectal carcinoma. Dis Colon Rectum; 2009 Jun;52(6):1166-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet-derived growth factor (subtype BB) is elevated in patients with colorectal carcinoma.
  • PURPOSE: Platelet-derived growth factor-BB plays a role in the development of vascular and lymphatic vessels in tumors.
  • In this study plasma levels of platelet-derived growth factor-BB were assessed preoperatively in patients with adenomas and colorectal cancer to determine whether platelet-derived growth factor-BB is a useful marker or prognostic indicator.
  • METHODS: Patients with adenomas and colorectal cancer undergoing resection were assessed.
  • RESULTS: One hundred seventy-nine patients were studied (91 with colorectal cancer, 88 with adenomas).
  • Preoperative colorectal cancer platelet-derived growth factor-BB levels were higher (1,771.1 pg/ml; confidence intervals, 1,429-2,065) than in the benign neoplasm group (1083 pg/ml; confidence intervals, 933-1,192, P < 0.001).
  • In patients with colorectal cancer, a direct relationship was noted between platelet-derived growth factor-BB levels and disease severity.
  • CONCLUSION: Platelet-derived growth factor-BB levels were greater in patients with colorectal cancer (vs. patients with adenoma) and rose with increasing disease severity.
  • [MeSH-major] Adenoma / blood. Colorectal Neoplasms / blood. Platelet-Derived Growth Factor / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Chi-Square Distribution. Enzyme-Linked Immunosorbent Assay. Female. Humans. Logistic Models. Male. Proto-Oncogene Proteins c-sis. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581863.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / platelet-derived growth factor BB
  •  go-up   go-down


23. Zhou X, Shang JQ, Zhou JN: [Transsacral local wide resection for mid-lower rectal tumors]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Jan;12(1):44-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transsacral local wide resection for mid-lower rectal tumors].
  • OBJECTIVE: To evaluate the efficacy of transsacral local wide resection for mid-lower rectal tumors.
  • METHODS: Clinical data of 133 patients undergone transsacral local wide resection for mid-lower rectal tumors between September 1994 and September 2005 were analyzed retrospectively.
  • Postoperative diagnosis was adenoma in 28 patients, hyperplastic polyp in 3 patients, carcinoid in 8 patients, gastrointestinal stromal tumor in 1 patient,adenoma with intra-mucosal carcinogenesis in 29 patients and adenocarcinoma invading into submucosa in 64 patients.
  • CONCLUSION: Transsacral local wide resection is simple and safe for mid-lower rectal tumors, which is an appropriate procedure for mid-lower rectal benign tumor and can serve as a sphincter-saving operation for selected T(1) lower rectal carcinoma.
  • [MeSH-major] Rectal Neoplasms / surgery. Sacrococcygeal Region / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145503.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Collinson RJ, McC Mortensen NJ: 'How I do it': TEM for tumors of the rectum. J Gastrointest Surg; 2009 Feb;13(2):359-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'How I do it': TEM for tumors of the rectum.
  • INTRODUCTION: Transanal endoscopic microsurgery (TEM) has an established role in the management of benign rectal tumors.
  • It also has an expanding role in the management of malignant tumors, which is more demanding for the clinician.
  • This paper discusses our institutional approach to TEM for benign and malignant tumors and covers some of the current management controversies.
  • [MeSH-major] Microsurgery / methods. Proctoscopy / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):429-37 [15747069.001]
  • [Cites] Dis Colon Rectum. 2002 May;45(5):601-4 [12004207.001]
  • [Cites] Dis Colon Rectum. 1995 Dec;38(12):1286-95 [7497841.001]
  • [Cites] Endoscopy. 1985 Jan;17(1):31-5 [3971938.001]
  • [Cites] Dig Surg. 2006;23(1-2):12-22 [16675907.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1546-52 [16252312.001]
  • [Cites] Int J Colorectal Dis. 2001 Nov;16(6):370-6 [11760898.001]
  • [Cites] Surg Endosc. 2006 Aug;20(8):1203-7 [16703429.001]
  • [Cites] Rev Esp Enferm Dig. 2006 Apr;98(4):234-40 [16792452.001]
  • [Cites] Br J Surg. 2007 May;94(5):627-33 [17335125.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):177-81 [7851173.001]
  • [Cites] Int J Colorectal Dis. 1986 Apr;1(2):79-84 [3611938.001]
  • [Cites] Colorectal Dis. 2000 Sep;2(5):252-63 [23578114.001]
  • [Cites] Dis Colon Rectum. 2001 Sep;44(9):1345-61 [11584215.001]
  • (PMID = 18461419.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Petrova TV, Nykänen A, Norrmén C, Ivanov KI, Andersson LC, Haglund C, Puolakkainen P, Wempe F, von Melchner H, Gradwohl G, Vanharanta S, Aaltonen LA, Saharinen J, Gentile M, Clarke A, Taipale J, Oliver G, Alitalo K: Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell; 2008 May;13(5):407-19
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype.
  • The Drosophila transcription factor Prospero functions as a tumor suppressor, and it has been suggested that the human counterpart of Prospero, PROX1, acts similarly in human cancers.
  • However, we show here that PROX1 promotes dysplasia in colonic adenomas and colorectal cancer progression.
  • PROX1 expression marks the transition from benign colon adenoma to carcinoma in situ, and its loss inhibits growth of human colorectal tumor xenografts and intestinal adenomas in Apc(min/+) mice, while its transgenic overexpression promotes colorectal tumorigenesis.
  • Furthermore, in intestinal tumors PROX1 is a direct and dose-dependent target of the beta-catenin/TCF signaling pathway, responsible for the neoplastic transformation.
  • Our data underscore the complexity of cancer pathogenesis and implicate PROX1 in malignant tumor progression through the regulation of cell polarity and adhesion.
  • [MeSH-major] Adenoma / genetics. Colonic Neoplasms / genetics. Homeodomain Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Carcinoma in Situ / genetics. Cell Line, Tumor. Colorectal Neoplasms / genetics. Disease Progression. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Phenotype. beta Catenin / physiology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455124.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United Kingdom / Worldwide Cancer Research / / 09-0791; United Kingdom / Medical Research Council / / G0301154
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Tumor Suppressor Proteins; 0 / beta Catenin; 0 / prospero-related homeobox 1 protein
  •  go-up   go-down


26. Amato A: Colorectal gastrointestinal stromal tumor. Tech Coloproctol; 2010 Nov;14 Suppl 1:S91-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal gastrointestinal stromal tumor.
  • Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm arising in the digestive tract, with an estimated prevalence of 15-20 per 1,000,000.
  • Colorectal GISTs represent about 5-10% of the cases, mainly located in the rectum that is the third common site.
  • Benign GISTs are more common, but many tumors are of uncertain malignant potential; tumor size and rate of mitosis are still the most reliable criteria for assessing the risk of an aggressive behavior.
  • Surgery is the first-line treatment for resectable non-metastatic colorectal GIST.
  • Segmental colectomy with negative margins is recommended, and local excision is oncologically adequate in highly selected rectal tumors.
  • [MeSH-major] Colorectal Neoplasms. Gastrointestinal Stromal Tumors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1178-86 [14515284.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):705-12 [11034250.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S37-8 [12528771.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):383-9 [11296107.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):89-96 [17145623.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):2006-11 [12957454.001]
  • [Cites] Int J Colorectal Dis. 2007 Aug;22(8):981-2 [16583196.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Eur J Surg Oncol. 2004 Dec;30(10):1098-103 [15522557.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Dis Colon Rectum. 2006 May;49(5):609-15 [16552495.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):14-24 [17072676.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S60-5 [12528774.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):526-32 [17139461.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1316-9 [15793646.001]
  • [Cites] J Surg Oncol. 2009 Jan 1;99(1):42-7 [18942073.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):109-14 [16639561.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1091-5 [11021812.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):625-41 [12717247.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Feb;18(2):147-51 [12542597.001]
  • [Cites] Am J Surg. 2006 Jan;191(1):121-3 [16399120.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2325-31 [16710031.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):937-45 [10435564.001]
  • [Cites] Gastroenterol Clin Biol. 2007 Jun-Jul;31(6-7):585-93 [17646785.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):728-34 [9720500.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1922-9 [15622586.001]
  • [Cites] Pol J Pathol. 2003;54(1):3-24 [12817876.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3282-90 [15161681.001]
  • [Cites] Surg Today. 2007;37(6):455-9 [17522761.001]
  • [Cites] Surg Today. 2007;37(8):698-701 [17643218.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):66-74 [10618607.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):791-5 [10702394.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1134-42 [11048809.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):332-9 [12594669.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14 ):2012-20 [12957455.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):889-94 [15223958.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):278-81 [9891765.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8118-21 [11719439.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):947-57 [10895817.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):53-60 [9916918.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):660-7 [12949711.001]
  • [Cites] Scand J Surg. 2003;92(3):195-9 [14582540.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1339-52 [11023095.001]
  • [Cites] Colorectal Dis. 2008 Nov;10 (9):951-2 [18294266.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S83-7 [12528778.001]
  • (PMID = 20967481.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


27. Griniatsos J, Michail O: Appendiceal neuroendocrine tumors: Recent insights and clinical implications. World J Gastrointest Oncol; 2010 Apr 15;2(4):192-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appendiceal neuroendocrine tumors: Recent insights and clinical implications.
  • New insights emerged last decade that enriched our knowledge regarding the biological behavior of appendiceal neuroendocrine tumors (NETs), which range from totally benign tumors less than 1cm to goblet cell carcinomas which behave similarly to colorectal adenocarcinoma.
  • Since the diagnosis is usually established post-appendicectomy, current recommendations focus on the early detection of:.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160597.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999180
  • [Keywords] NOTNLM ; Appendiceal carcinoids / Goblet cell carcinoma / Neuroendocrine tumors / Right hemicolectomy
  •  go-up   go-down


28. Arnold CN, Nagasaka T, Goel A, Scharf I, Grabowski P, Sosnowski A, Schmitt-Gräff A, Boland CR, Arnold R, Blum HE: Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors. Int J Cancer; 2008 Oct 1;123(7):1556-64
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors.
  • To better understand the molecular pathogenesis of neuroendocrine tumors (NET), we investigated the molecular and clinical characteristics of malignant poorly differentiated colorectal NET and compared these findings with sporadic CRC and well-differentiated benign and malignant fore-/midgut NET.
  • Tumors were analyzed and correlated for microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP).
  • A total of 34 malignant poorly differentiated colorectal NET, 38 well-differentiated benign and malignant fore-/midgut-NET and 150 sporadic colorectal cancers (CRC) with known MSI status were investigated.
  • Of the 34 colorectal NET, 0/1 of the MSI-H, 3/5 (60%) of the MSI-L and 13/19 (68%) of the MSS tumors were CIMP+ (p = 0.17).
  • Of the fore-/midgut-NET, none was MSI-H. 20/34 (59%) colorectal NET vs. 11/38 (29%) fore-/midgut-NET were CIMP+ (p = 0.01).
  • The Ki-67 index was significantly higher in poorly differentiated colorectal NET compared to the less malignant fore-/midgut-NET (p < 0.0001).
  • We conclude that molecular pathogenesis in sporadic CRC and poorly differentiated colorectal NET is different despite some similarities.
  • Main differences between malignant well-differentiated and poorly differentiated NET are the Ki-67 proliferation rate and differential methylation in tumor-associated genes.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. Colorectal Neoplasms / mortality. Neuroendocrine Tumors / genetics. Neuroendocrine Tumors / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):947-57 [14871972.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2157-64 [17278096.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:199-208 [15153435.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):805-15 [15459661.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3075-9 [2039987.001]
  • [Cites] Nat Med. 1996 Mar;2(3):281-2 [8612223.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2545-50 [9122232.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):50-6 [9591634.001]
  • [Cites] Lancet. 1997 Oct 25;350(9086):1223 [9652567.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):11-6 [10389971.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):988-93 [15573120.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):855-60 [15613458.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):229-36 [15599934.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):256-60 [15842051.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):757-62 [17674042.001]
  • [Cites] Endocr Pathol. 2007 Fall;18(3):145-9 [18058263.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):38-45 [11790979.001]
  • [Cites] Virchows Arch. 2002 Sep;441(3):256-63 [12242522.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Feb;15(2):139-43 [12560757.001]
  • [Cites] Oncogene. 2003 Feb 13;22(6):924-34 [12584572.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):1367-73 [12629131.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1608-14 [12670912.001]
  • [Cites] Diagn Mol Pathol. 2003 Dec;12(4):181-6 [14639103.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):570-6 [10747315.001]
  • [Cites] Ann Surg. 2000 Oct;232(4):549-56 [10998653.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1097-103 [11021813.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4073-81 [11051259.001]
  • [Cites] Oncology. 2000 Sep;59(3):229-37 [11053991.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):4146-56 [11095446.001]
  • [Cites] Gut. 2001 Apr;48(4):536-41 [11247899.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Apr;13(4):405-11 [11338071.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5905-10 [11479232.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Neuroendocrinology. 2005;81(1):1-9 [15809513.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Aug;3(8):761-71 [16234004.001]
  • [Cites] Int J Colorectal Dis. 2006 Apr;21(3):221-30 [16485142.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • (PMID = 18646189.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA072851; United States / NCI NIH HHS / CA / R01 CA072851-13
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS187521; NLM/ PMC2851204
  •  go-up   go-down


29. Falguières T, Maak M, von Weyhern C, Sarr M, Sastre X, Poupon MF, Robine S, Johannes L, Janssen KP: Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol Cancer Ther; 2008 Aug;7(8):2498-508
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool.
  • The targeting of solid tumors requires delivery tools that resist intracellular and extracellular inactivation, and that are taken up specifically by tumor cells.
  • We have shown previously that the recombinant nontoxic B-subunit of Shiga toxin (STxB) can serve as a delivery tool to target digestive tumors in animal models.
  • The aim of this study was to expand these experiments to human colorectal cancer.
  • Tissue samples of normal colon, benign adenomas, colorectal carcinomas, and liver metastases from 111 patients were obtained for the quantification of the expression of the cellular STxB receptor, the glycosphingolipid globotriaosyl ceramide (Gb(3) or CD77).
  • We found that compared with normal tissue, the expression of Gb(3) was strongly increased in colorectal adenocarcinomas and their metastases, but not in benign adenomas.
  • Of a given tumor sample, on average, 80% of the cells could visibly bind STxB, and upon incubation at 37 degrees C, STxB was transported to the Golgi apparatus, following the retrograde route.
  • This STxB-specific intracellular targeting allows the molecule to avoid recycling and degradation, and STxB could consequently be detected on tumor cells even 5 days after initial uptake.
  • In conclusion, the targeting properties of STxB could be diverted for the delivery of contrast agents to human colorectal tumors and their metastases, whose early detection and specific targeting remains one of the principal challenges in oncology.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / biosynthesis. Colorectal Neoplasms / therapy. Intestines / microbiology. Shiga Toxins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromatography, Thin Layer. Female. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Trihexosylceramides / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18687997.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Gb3 antigen; 0 / Shiga Toxins; 0 / Trihexosylceramides; 0 / stxB toxin; 71965-57-6 / globotriaosylceramide
  •  go-up   go-down


30. Gottwald L, Korczyński J, Góra E, Bieńkiewicz A: [Adnexal tumors after surgical treatment of colorectal cancer]. Ginekol Pol; 2008 Apr;79(4):259-63
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adnexal tumors after surgical treatment of colorectal cancer].
  • OBJECTIVE: The risk of metastatic ovarian tumor is significantly higher in case of women with a history of colorectal cancer.
  • DESIGN: The purpose of the study was to evaluate the clinical presentation and histopathology of adnexal tumors in case of female patients with a history of colorectal adenocarcinoma.
  • MATERIAL AND METHODS: A retrospective study on 13 women (each with a history of colorectal carcinoma, operated due to adnexal tumor between 2004 and 2007), has been conducted.
  • Subject characteristics, ultrasound, CT, serum tumor markers levels, histopathology and findings at surgery were analyzed.
  • RESULTS: Time distance between colorectal cancer surgery and ovarian tumor operation - measured in months -was shorter in cases of malignant neoplasms (10.13 +/- 3.98) than in benign tumors (26.2 +/- 19.37).
  • Ultrasound examination showed solid-cystic adnexal tumors in 8 malignant cases, and ovarian cysts in 5 benign conditions.
  • Unilateral adnexectomy only took place in one case of benign tumor and in one case of disseminated neoplasmatic disease.
  • CONCLUSIONS: When evaluating a patient with an adnexal tumor, a history of malignancy strongly suggests a metastatic nature.
  • The use of ultrasound associated with plasma levels of Ca 125, Ca 19-9 and CEA, represents a useful method of preoperative assessment of ovarian tumors.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Female. Humans. Middle Aged. Neoplasm Staging. Poland. Retrospective Studies. Risk Assessment. Ultrasonography, Doppler, Color / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592863.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


31. Kurimoto M, Fukuda I, Hizuka N, Takano K: The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocr J; 2008 Mar;55(1):67-71
Genetic Alliance. consumer health - Acromegaly.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence of benign and malignant tumors in patients with acromegaly at a single institute.
  • It has been reported that patients with acromegaly may have an increased risk of developing several types of cancers, such as colorectal, breast and prostate tumors.
  • In this study, we determined the prevalence of benign and malignant neoplasms in patients with acromegaly.
  • Of the benign tumors, multinodular goiter and colonic, gastric and gallbladder polyps were observed in 57% (47/83), 40% (35/87), 23% (10/43), and 14% (11/77) [corrected] of the patients, respectively.
  • [MeSH-major] Acromegaly / complications. Acromegaly / epidemiology. Neoplasms / complications. Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / complications. Breast Neoplasms / epidemiology. Carcinoma / complications. Carcinoma / epidemiology. Colonic Neoplasms / complications. Colonic Neoplasms / epidemiology. Female. Humans. Incidence. Leiomyosarcoma / complications. Leiomyosarcoma / epidemiology. Male. Middle Aged. Prevalence. Retrospective Studies. Stomach Neoplasms / complications. Stomach Neoplasms / epidemiology. Thyroid Diseases / complications. Thyroid Diseases / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Endocr J. 2008 Aug;55(4):786
  • (PMID = 18202526.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


32. Yang BL, Gu YF, Shao WJ, Chen HJ, Sun GD, Jin HY, Zhu X: Retrorectal tumors in adults: magnetic resonance imaging findings. World J Gastroenterol; 2010 Dec 14;16(46):5822-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrorectal tumors in adults: magnetic resonance imaging findings.
  • AIM: To retrospectively evaluate the magnetic resonance imaging (MRI) features of adult retrorectal tumors and compare with histopathologic findings.
  • METHODS: MRI features of 21 patients with preoperative suspicion of retrorectal tumors were analyzed based on the histopathological and clinical data.
  • RESULTS: Fourteen benign cystic lesions appeared hypointense on T1-weighted images, and hyperintense on T2-weighted images with regular peripheral rim.
  • Six solid tumors were malignant lesions and showed heterogeneous intensity on MRI.
  • Gastrointestinal stromal tumors displayed low signal intensity on T1-weighted images, and intermediate to high signal intensity on T2-weighted images.
  • CONCLUSION: MRI is a helpful technique to define the extent of the retrorectal tumor and its relationship to the surrounding structures, and also to demonstrate possible complications so as to choose the best surgical approach.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1985 Nov;28(11):855-8 [4053899.001]
  • [Cites] Eur Radiol. 2004 Oct;14(10):1926-9 [15300393.001]
  • [Cites] Oncology. 1993 Nov-Dec;50(6):495-9 [8233293.001]
  • [Cites] J Comput Assist Tomogr. 1997 Sep-Oct;21(5):731-2 [9294562.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jun;170(6):1488-90 [9609159.001]
  • [Cites] Dis Colon Rectum. 1998 Aug;41(8):1056-8 [9715165.001]
  • [Cites] Clin Imaging. 2005 Jul-Aug;29(4):251-4 [15967315.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1581-7 [15937630.001]
  • [Cites] Yonsei Med J. 2005 Aug 31;46(4):555-61 [16127782.001]
  • [Cites] AJR Am J Roentgenol. 2006 Aug;187(2):517-21 [16861558.001]
  • [Cites] Int J Colorectal Dis. 2007 Apr;22(4):381-5 [16909248.001]
  • [Cites] Br J Surg. 2008 Feb;95(2):214-21 [17933000.001]
  • [Cites] Abdom Imaging. 2008 Jul-Aug;33(4):498-500 [17680300.001]
  • [Cites] Eur Radiol. 2008 Nov;18(11):2586-93 [18566821.001]
  • [Cites] Can J Surg. 2008 Dec;51(6):E115-6 [19057717.001]
  • [Cites] Am Surg. 2009 Mar;75(3):240-8 [19350861.001]
  • [Cites] Am J Gastroenterol. 2000 May;95(5):1344-7 [10811351.001]
  • [Cites] Radiographics. 2001 May-Jun;21(3):575-84 [11353107.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):705-14 [12023574.001]
  • [Cites] Tech Coloproctol. 2002 Apr;6(1):43-9 [12077641.001]
  • [Cites] Hum Pathol. 2002 May;33(5):456-8 [12094369.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):655-64 [12424067.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51 [12528772.001]
  • [Cites] Surg Oncol. 2003 Jul;12(1):21-6 [12689667.001]
  • [Cites] Tech Coloproctol. 2003 Apr;7(1):55-7 [12750956.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):880-6 [12788424.001]
  • [Cites] Eur Radiol. 2003 Aug;13(8):2053-4 [12942309.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):644-52 [2996861.001]
  • (PMID = 21155003.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3001973
  •  go-up   go-down


33. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP, National Academy of Clinical Biochemistry: National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem; 2008 Dec;54(12):e11-79
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
  • BACKGROUND: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed.
  • METHODS: Published reports relevant to use of tumor markers for 5 cancer sites--testicular, prostate, colorectal, breast, and ovarian--were critically reviewed.
  • RESULTS: For testicular cancer, alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. alpha-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors.
  • Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 microg/L.
  • In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease.
  • CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer.
  • CONCLUSIONS: Implementation of these recommendations should encourage optimal use of tumor markers.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. Clinical Laboratory Techniques. Colorectal Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis. Prostatic Neoplasms / diagnosis. Testicular Neoplasms / diagnosis


34. Schmidt WM, Sedivy R, Forstner B, Steger GG, Zöchbauer-Müller S, Mader RM: Progressive up-regulation of genes encoding DNA methyltransferases in the colorectal adenoma-carcinoma sequence. Mol Carcinog; 2007 Sep;46(9):766-72
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive up-regulation of genes encoding DNA methyltransferases in the colorectal adenoma-carcinoma sequence.
  • Here, we investigated the expression of DNA demethylase and three DNA methyltransferases during colorectal tumorigenesis comparing the genes encoding DNA methyltransferases 1 (DNMT1), 3A, and 3B (DNMT3A and DNMT3B) with methyl-CpG binding domain protein 2 (MBD2), recently described as the only active DNA demethylase.
  • Total RNA isolated from normal colonic mucosa (n = 24), benign adenomas (n = 18), and malignant colorectal carcinomas (n = 32) was analyzed by reverse transcriptase-PCR with subsequent quantification by capillary gel electrophoresis.
  • In contrast to MBD2, expression of DNMT1 and DNMT3A increased in parallel to the degree of dysplasia, with significant overexpression in the malignant lesion when compared with mucosa or with benign lesions (DNMT1).
  • Pairwise comparisons between tumors and matched, adjacent healthy mucosa tissue (n = 13) revealed that expression of all three genes encoding DNA methyltransferases increased by two- to three-fold.
  • Our data suggest a relevant role of the DNA methyltransferases during colorectal tumorigenesis.
  • [MeSH-major] Adenoma / enzymology. Colorectal Neoplasms / enzymology. DNA Modification Methylases / metabolism. Gene Expression Regulation, Neoplastic. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17538945.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DMAP1 protein, human; 0 / DNA-Binding Proteins; 0 / MBD2 protein, human; 0 / Repressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA methyltransferase 3A; EC 2.1.1.37 / DNA methyltransferase 3B
  •  go-up   go-down


35. Lewis MR, Deavers MT, Silva EG, Malpica A: Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol; 2006 Feb;30(2):177-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge.
  • Ovarian involvement by metastatic colorectal adenocarcinoma, although not an uncommon occurrence, remains a diagnostic challenge.
  • The gross and histologic features of such metastases overlap those of primary ovarian epithelial neoplasms such as endometrioid or mucinous adenocarcinoma.
  • The clinical and pathologic features of 86 cases of metastatic colorectal adenocarcinoma involving the ovary were reviewed.
  • Presenting symptoms included abdominal or pelvic pain (45 cases), rectal bleeding (13 cases), change in bowel habits (20 cases), and vaginal bleeding (5 cases).
  • Many involved ovaries featured smooth capsules without gross evidence of surface involvement by tumor.
  • In general, the tumors had typical histologic features of metastatic colorectal adenocarcinoma, including a garland pattern and dirty necrosis.
  • In 23 cases, foci with a benign or low malignant potential appearance were seen.
  • Immunohistochemical studies showed that 29 of 29 tumors (100%) were positive for CK20; focal CK7 positivity was seen in 5 of 30 cases (17%).
  • Metastatic colorectal adenocarcinoma should be considered in the differential diagnosis of an ovarian mass, even if the mass is large and unilateral or in a young patient, to secure proper treatment of these patients.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434891.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


36. Robles R, Abellán B, Marín C, Fernández JA, Ramírez P, Morales D, Ramírez M, Sánchez F, Parrilla P: [Laparoscopic resection of solid liver tumors. Presentation of our experience]. Cir Esp; 2005 Oct;78(4):238-45
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic resection of solid liver tumors. Presentation of our experience].
  • INTRODUCTION: Laparoscopic liver resection (LLR) of solid liver tumors (SLT) has not become widespread due to technical problems, the risk of air embolism, and possible tumoral spread in malignant lesions.
  • Preoperative diagnosis was liver metastases from colorectal carcinoma in 11 patients and benign tumor in the remaining five patients.
  • VII) and two local resections of benign tumors.
  • CONCLUSION: LLR of benign SLTs shows all the advantages of laparoscopy.
  • [MeSH-major] Hepatectomy / methods. Laparoscopy. Liver Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420832.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


37. Reddy RM, Fleshman JW: Colorectal gastrointestinal stromal tumors: a brief review. Clin Colon Rectal Surg; 2006 May;19(2):69-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal gastrointestinal stromal tumors: a brief review.
  • Gastrointestinal stromal tumors (GISTs) are rare lesions that constitute the majority of mesenchymal tumors in the gastrointestinal tract.
  • Although many lesions may be benign, up to half of patients develop recurrent disease within a few years.
  • Radiologic examinations can be helpful in initial diagnosis and staging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2004 Feb;53(2):235-40 [14724156.001]
  • [Cites] J Nucl Med. 2004 Mar;45(3):357-65 [15001674.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] Ann Diagn Pathol. 2003 Dec;7(6):337-47 [15018116.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):142-50 [15232741.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):377-89 [10199467.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):937-45 [10435564.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):946-54 [10435565.001]
  • [Cites] Dis Colon Rectum. 1999 Aug;42(8):1085-8 [10458136.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4297-300 [10485475.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1213-20 [10534170.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1157-63 [10751339.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3211-20 [10986053.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1316-8 [11005505.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1339-52 [11023095.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):705-12 [11034250.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1134-42 [11048809.001]
  • [Cites] Br J Radiol. 2000 Sep;73(873):1010-2 [11064658.001]
  • [Cites] Eur Radiol. 2001;11(2):216-9 [11218017.001]
  • [Cites] J Pathol. 2001 Apr;193(4):505-10 [11276010.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Mar;13(3):283-6 [11293450.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):578-82 [11431711.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):5054-8 [11526490.001]
  • [Cites] Mod Pathol. 2001 Oct;14(10):950-6 [11598163.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):669-76 [12152168.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3034-8 [12374669.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51 [12528772.001]
  • [Cites] Radiology. 2003 Feb;226(2):527-32 [12563150.001]
  • [Cites] Surg Oncol. 2003 Jul;12(1):21-6 [12689667.001]
  • [Cites] Mod Pathol. 2003 Apr;16(4):366-75 [12692202.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jun;180(6):1607-12 [12760929.001]
  • [Cites] Pol J Pathol. 2003;54(1):3-24 [12817876.001]
  • [Cites] Cancer. 1962 Mar-Apr;15:400-9 [13917556.001]
  • [Cites] J Comput Assist Tomogr. 2004 Nov-Dec;28(6):811-7 [15538156.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s155-7 [15655606.001]
  • [Cites] Indian J Cancer. 2004 Oct-Dec;41(4):175-7 [15659872.001]
  • [Cites] ANZ J Surg. 2005 Mar;75(3):165-72 [15777399.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1316-9 [15793646.001]
  • [Cites] Eur J Radiol. 2005 Apr;54(1):118-23 [15797301.001]
  • [Cites] Pathol Oncol Res. 2005;11(1):11-21 [15800677.001]
  • [Cites] G Chir. 2005 Apr;26(4):135-7 [16035248.001]
  • [Cites] J Chin Med Assoc. 2005 Jul;68(7):291-8 [16038368.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5795-804 [16110036.001]
  • [Cites] Hum Pathol. 1992 Jul;23(7):762-7 [1612575.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1781-8 [16136600.001]
  • [Cites] Am J Surg Pathol. 1986;10 Suppl 1:83-99 [3296804.001]
  • [Cites] Ann Surg. 1987 Dec;206(6):706-10 [3689007.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] Ann Surg Oncol. 1995 Jan;2(1):26-31 [7834450.001]
  • [Cites] Gastrointest Endosc. 1997 Jun;45(6):468-73 [9199902.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):728-34 [9720500.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):82-7 [9888707.001]
  • [Cites] Ann Surg. 1991 Nov;214(5):569-74 [1953109.001]
  • [Cites] J Comput Assist Tomogr. 2003 Sep-Oct;27(5):792-8 [14501372.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1178-86 [14515284.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1454-6 [14571762.001]
  • [Cites] Am J Surg. 2003 Dec;186(6):665-9 [14672776.001]
  • (PMID = 20011313.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780110
  • [Keywords] NOTNLM ; CD117/c-kit / Gastrointestinal stromal tumors / colon cancer / imatinib mesylate / surgery
  •  go-up   go-down


38. Czeczot H, Scibior-Bentkowska D, Skrzycki M, Majewska M, Podsiad M: [Lipid peroxidation level in gastrointestinal tract tumors]. Pol Merkur Lekarski; 2010 Nov;29(173):309-14
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lipid peroxidation level in gastrointestinal tract tumors].
  • Oxygen free radicals and their reactive derivatives participate in formation of chronic inflammation states, which facilitate development of gastrointestinal tract tumors.
  • The aim of the study was the determination of lipid peroxidation level in gastrointestinal tract tumors (stomach, liver, colon, and colorectal cancer to liver metastases).
  • MATERIAL AND METHODS: Materials for studies were obtained from 150 patients with gastrointestinal tract tumors: 10 with stomach cancer, 30 with malignant and benign liver cancers, 60 with primary colorectal cancer, and 50 with metachronous colorectal cancer liver metastases.
  • Tumor specimens, and normal adjacent tissues (6-7 cm from the edge of the tumor), which served as control tissue in studies, were collected from patients (with their consent) during surgery.
  • RESULTS: The study showed the highest concentration of TBARS in benign, and the lowest in malignant liver tumors.
  • Other types of gastrointestinal tumors studied, were characterized by similar levels of lipid peroxidation.
  • TBARS concentration in these tumors was approximately 2-fold higher than in malignant liver tumors and much lower than in benign tumors.
  • In all cancers of the digestive tract with the exception of malignant liver tumors increased level of TBARS was found, comparing with control tissue.
  • The level of lipid peroxidation in liver cirrhosis and malignant liver tumors was similar.
  • There were no significant differences in TBARS concentration in the tumors of particular sections of the intestine and normal colon.
  • The highest concentration of TBARS was found in G1 grade of colorectal cancer.
  • The highest level of lipid peroxidation, expressed as the concentration of TBARS was found in the I stage of colorectal cancer clinical advancement.
  • The changes of lipid peroxidation level--a marker of oxidative stress in gastrointestinal tumors appear to be closely associated with their development stages (liver cirrhosis/malignant liver cancer; colorectal cancer/colorectal cancer liver metastases) and are likely to create such conditions, in which cancerous cells may proliferate, undergo gradual dedifferentiation and malignancy, and generate metastases.
  • [MeSH-major] Gastrointestinal Neoplasms / metabolism. Lipid Peroxidation. Liver Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21268915.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


39. Yaramov N, Sokolov M, Angelov K, Petrov B, Pavlov B: [Retrorectal tumors--15 years experience and literary review]. Khirurgiia (Sofiia); 2010;(1):9-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retrorectal tumors--15 years experience and literary review].
  • PURPOSE: Tumors occurring in the retrorectal space are heterogeneous and uncommon.
  • This study examined the diagnosis, treatment, and outcome ofretrorectal tumors at a tertiary referral center.
  • METHODS: Patients with primary, extramucosal neoplasms occurring in the retrorectal space were identified using a retropectively maintained, procedural database of all adult colorectal surgical patients (1995-2009).
  • Exclusion criteria included inflammatory processes, locally advanced colorectal cancer, and metastatic malignancy.
  • RESULTS: Thirty-eight patients with retrorectal tumors were treated.
  • Malignant tumors comprised 21 percent.
  • All benign tumors were resected with normal histologic margins and none recurred.
  • CONCLUSIONS: Retrorectal tumors remain a diagnostic and therapeutic challenge.
  • Various imaging modalities are useful for planning resection but cannot establish a definitive diagnosis.
  • Whereas benign retrorectal tumors can be completely resected, curative resection of malignant retrorectal tumors remains difficult.
  • [MeSH-major] Chordoma / pathology. Chordoma / surgery. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery. Rectum / pathology. Rectum / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21972697.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


40. Toll A, Real FX: Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next? Cell Cycle; 2008 Sep 1;7(17):2674-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next?
  • Somatic oncogenic activating mutations in FGFR3 and/or PIK3CA have recently been described in benign epithelial cutaneous lesions that never progress to malignancy (seborrheic keratoses and epidermal nevi).
  • The same mutations have been observed in malignant neoplasms from other tissues (bladder carcinoma, cervix cancer, colorectal cancer, myeloma).
  • However, many of the abovementioned epithelial benign cutaneous tumors do not harbour mutations in FGFR3 or PIK3CA.
  • [MeSH-major] Mutation / genetics. Skin Neoplasms / genetics. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728396.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 82
  •  go-up   go-down


41. Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, Zhu RM, Li GL, Xia XY, Wei XW, Ji HZ, Lu H, Gao Y, Gao WM, Chen LB: Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol; 2008 May 21;14(19):3074-80
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients.
  • AIM: To evaluate the diagnostic role of serum RASSF1A promoter hypermethylation in gastric and colorectal adenocarcinoma.
  • METHODS: Methylation-specific polymerase chain reaction (MSPCR) was used to examine the promoter methylation status of the serum RASSF1A gene in 47 gastric adenocarcinoma patients, 45 colorectal adenocarcinoma patients, 60 patients with benign gastrointestinal disease (30 with benign gastric disease and 30 with benign colorectal disease), and 30 healthy donor controls.
  • A paired study of RASSF1A promoter methylation status in primary tumor, adjacent normal tissue, and postoperative serum were conducted in 25 gastric and colorectal adenocarcinoma patients who later were underwent surgical therapy.
  • RESULTS: The frequencies of detection of serum RASSF1A promoter hypermethylation in gastric (34.0%) and colorectal (28.9%) adenocarcinoma patients were significantly higher than those in patients with benign gastric (3.3%) or colorectal (6.7%) disease or in healthy donors (0%) (P < 0.01).
  • The methylation status of RASSF1A promoter in serum samples was consistent with that in paired primary tumors, and the MSPCR results for RASSF1A promoter methylation status in paired preoperative samples were consistent with those in postoperative serum samples.
  • The serum RASSF1A promoter hypermethylation did not correlate with patient sex, age, tumor differentiation grade, surgical therapy, or serum carcinoembryonic antigen level.
  • CONCLUSION: Aberrant CpG island methylation within the promoter region of RASSF1A is a promising biomarker for gastric and colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. DNA Methylation. DNA, Neoplasm / blood. Promoter Regions, Genetic. Stomach Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2000 Dec;30(3):211-4 [11147802.001]
  • [Cites] Oncol Rep. 2007 Nov;18(5):1225-30 [17914577.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7034-8 [11585730.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(12):4309-18 [12024041.001]
  • [Cites] Oncogene. 2002 May 23;21(23):3792-5 [12032847.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1761-6 [12060614.001]
  • [Cites] Oncogene. 2002 Oct 17;21(47):7277-82 [12370819.001]
  • [Cites] Int J Cancer. 2002 Dec 20;102(6):623-8 [12448005.001]
  • [Cites] J Pathol. 2003 May;200(1):23-31 [12692837.001]
  • [Cites] Cancer Lett. 2003 Apr 25;193(2):207-16 [12706879.001]
  • [Cites] Cancer Lett. 2003 May 8;194(1):99-105 [12706863.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8125-36 [14603253.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):96-100 [15185349.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4244-50 [15205337.001]
  • [Cites] Cancer Res. 1977 Mar;37(3):646-50 [837366.001]
  • [Cites] Oncology. 1989;46(5):318-22 [2779946.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5):556-60 [10528904.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3441-54 [15526363.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1219-25 [15709192.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1141-5 [15734995.001]
  • [Cites] Histol Histopathol. 2005 Apr;20(2):645-63 [15736067.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3682-90 [15867363.001]
  • [Cites] Biochemistry (Mosc). 2005 May;70(5):576-83 [15948711.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1293-6 [16001680.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5205-10 [16051962.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7653-9 [16140931.001]
  • [Cites] Oncogene. 2005 Nov 17;24(51):7630-4 [16007118.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):339-46 [16139926.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):315-9 [10888881.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):35669-72 [10998413.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):192-8 [16482617.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):4557-63 [16344548.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Lung Cancer. 2007 May;56(2):289-94 [17267069.001]
  • [Cites] BMC Cancer. 2007;7:120 [17608924.001]
  • [Cites] Int J Surg Pathol. 2007 Jul;15(3):242-51 [17652530.001]
  • [Cites] J Cell Sci. 2007 Sep 15;120(Pt 18):3163-72 [17878233.001]
  • [Cites] Mol Cell. 2007 Sep 21;27(6):962-75 [17889669.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):691-9 [11333291.001]
  • (PMID = 18494062.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2712178
  •  go-up   go-down


42. Ji BT, Weissfeld JL, Chow WH, Huang WY, Schoen RE, Hayes RB: Tobacco smoking and colorectal hyperplastic and adenomatous polyps. Cancer Epidemiol Biomarkers Prev; 2006 May;15(5):897-901
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tobacco smoking and colorectal hyperplastic and adenomatous polyps.
  • Colorectal adenomas and possibly some hyperplastic polyps are precursors of colorectal cancer.
  • Tobacco use is associated in epidemiologic studies with these polyps, although links between smoking and colorectal cancer are less consistent.
  • To characterize the role of tobacco in early colorectal carcinogenesis, we compared tobacco use among 4,383 subjects with histologically verified benign (hyperplastic or adenomatous) polyps of the distal colon (descending colon, sigmoid, and rectum) with tobacco use among 33,667 subjects who were endoscopy negative for distal colon tumors, in the screening arm of the Prostate, Lung, Colorectal, and Ovarian Trial, a randomized trial of flexible sigmoidoscopy.
  • [MeSH-major] Adenomatous Polyposis Coli / etiology. Colorectal Neoplasms / etiology. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702367.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


43. Olesen SH, Christensen LL, Sørensen FB, Cabezón T, Laurberg S, Orntoft TF, Birkenkamp-Demtröder K: Human FK506 binding protein 65 is associated with colorectal cancer. Mol Cell Proteomics; 2005 Apr;4(4):534-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human FK506 binding protein 65 is associated with colorectal cancer.
  • We initiated the present study to identify new genes associated with colorectal cancer.
  • In a previously published microarray study an EST (W80763), later identified as the gene hFKBP10 (NM_021939), was found to be strongly expressed in tumors while absent in the normal mucosa.
  • Here we describe this gene hFKBP10 together with its encoded protein hFKBP65 as a novel marker associated with colorectal cancer.
  • Analysis of 31 colorectal adenocarcinomas and 14 normal colorectal mucosa by RealTime PCR for hFKBP10 showed a significant up-regulation in tumors, when compared with normal mucosa.
  • Immunohistochemical analysis of 26 adenocarcinomas and matching normal mucosa, as well as benign hyperplastic polyps and adenomas, using a monoclonal anti-hFKBP65 antibody, showed that the protein was not present in normal colorectal epithelial cells, but strongly expressed in the tumor cells of colorectal cancer.
  • The protein was also expressed in fibroblasts of both normal mucosa and tumor tissue.
  • Western blot analysis of matched tumors and normal mucosa supported the finding of increased hFKBP65 expression in tumors compared with normal mucosa, in addition to identifying the molecular mass of hFKBP65 to approximately 72 kDa.
  • In conclusion, the protein hFKBP65 is associated with colorectal cancer, and we hypothesize the protein to be involved in fibroblast and transformed epithelial cell-specific protein synthesis in the endoplasmic reticulum.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Tacrolimus Binding Proteins / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671042.001).
  • [ISSN] 1535-9476
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; EC 5.2.1.- / Tacrolimus Binding Proteins
  •  go-up   go-down


44. Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D, Pachlewski J, Oledzki J, Ostrowski J: Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One; 2010;5(10)
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability.
  • BACKGROUND: Clinical progression of colorectal cancers (CRC) may occur in parallel with distinctive signaling alterations.
  • Based on a consensus of the results obtained by two normalization algorithms, and two probe set sorting criteria, we identified 14 and 17 KEGG signaling and metabolic pathways that are significantly altered between normal and tumor samples and between benign and malignant tumors, respectively.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Oligonucleotide Array Sequence Analysis. Oncogenes. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3124-30 [11306497.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3544-9 [11325815.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):509-19 [11395427.001]
  • [Cites] Neoplasia. 2001 Sep-Oct;3(5):395-401 [11687950.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4352-63 [12154040.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Gut. 2003 Aug;52(8):1148-53 [12865273.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):323-31 [14960458.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1377-91 [14973550.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):335-51 [10448282.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):480-6 [15685558.001]
  • [Cites] Genome Biol. 2005;6(2):R16 [15693945.001]
  • [Cites] Oncol Rep. 2005 Mar;13(3):517-24 [15706427.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1587-97 [15735049.001]
  • [Cites] BMC Bioinformatics. 2005;6:80 [15799785.001]
  • [Cites] Int J Colorectal Dis. 2005 Sep;20(5):391-402 [15883783.001]
  • [Cites] Expert Rev Mol Diagn. 2006 May;6(3):465-80 [16706747.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1829-36 [16721809.001]
  • [Cites] J Mol Med (Berl). 2006 Oct;84(10):872-82 [16924468.001]
  • [Cites] World J Gastroenterol. 2006 Nov 21;12(43):6998-7006 [17109495.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):103-37 [17010523.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] J Mol Med (Berl). 2007 Jul;85(7):733-43 [17415542.001]
  • [Cites] Cancer Detect Prev. 2007;31(4):282-95 [17936523.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Mol Cancer Res. 2007 Dec;5(12):1263-75 [18171984.001]
  • [Cites] Mol Cancer. 2007;6:79 [18081933.001]
  • [Cites] BMC Bioinformatics. 2008;9:140 [18318917.001]
  • [Cites] BMC Bioinformatics. 2008;9:164 [18366762.001]
  • [Cites] Surg Clin North Am. 2008 Aug;88(4):681-704, v [18672136.001]
  • [Cites] Dis Markers. 2008;25(1):1-16 [18776587.001]
  • [Cites] Nat Biotechnol. 2008 Sep;26(9):1003-10 [18711341.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2835-45 [18843029.001]
  • [Cites] World J Gastroenterol. 2008 Oct 14;14(38):5887-92 [18855989.001]
  • [Cites] Biotechniques. 2008 Nov;45(5):501-20 [19007336.001]
  • [Cites] Cell Oncol. 2009;31(1):19-29 [19096147.001]
  • [Cites] Cancer Treat Rev. 2009 May;35(3):201-9 [19081199.001]
  • [Cites] Gastroenterology. 2009 Jul;137(1):165-75 [19328798.001]
  • [Cites] J Biomed Inform. 2009 Aug;42(4):605-11 [19535009.001]
  • [Cites] Expert Rev Mol Diagn. 2009 Sep;9(6):623-30 [19732006.001]
  • [Cites] Br J Cancer. 2010 Feb 16;102(4):765-73 [20087348.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):41-56 [17210682.001]
  • [ErratumIn] PLoS One. 2010;5(12) doi: 10.1371/annotation/8c585739-a354-4fc9-a7d0-d5ae26fa06ca. Ostrowsk, Jerzy [corrected to Ostrowski, Jerzy]
  • (PMID = 20957034.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2948500
  •  go-up   go-down


45. Cui M, Wang S, Ye YJ, Cui ZR, Ke Y: [Effect of tumor burden on differentiation of T lymphocytes in the peripheral blood of patients with colorectal cancer]. Zhonghua Yi Xue Za Zhi; 2007 Jan 2;87(1):16-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of tumor burden on differentiation of T lymphocytes in the peripheral blood of patients with colorectal cancer].
  • OBJECTIVE: To analyze the effect of tumor burden on the differentiation of T1 and T2 cells and its implication in patients with colorectal cancer.
  • METHODS: Peripheral venous blood samples were obtained from 20 patients with primary colorectal cancer before and 7 days after the operation, radical operation in 17 patients and palliative resection in 3 patients.
  • Twenty sex and age-matched patients with benign diseases treated in the same period were used as controls.
  • RESULTS: At the time of diagnosis, the percentage of T1 and T2 cells in the peripheral lymphocytes of the case group was lower significantly than that of the control group (P = 0.006, and P = 0.017).
  • After getting rid of the tumor burden, the percentage of T1 cells increased, however, not significantly (P > 0.05).
  • The percentages of T1 cell of the patients with the tumor > or = 5 cm and of the patients with poorly differentiated tumors were significantly lower than those of the patients with the tumor < 5 cm and of the patients with well or moderately differentiated tumors (P = 0.064, and P = 0.072).
  • The percentage of T1 cells in the patients with lymph node metastasis and stage III approximately IV tumor were lower significantly than those of the patients without lymph node metastasis and those with stage I approximately II tumor (P = 0.033 and P = 0.033).
  • No significant differences were found between the population of T1 cells and such factors as tumor size, serosa invasion, and distant metastasis.
  • CONCLUSION: Tumor load suppresses the differentiation of T1 and T2 cells in the patients with colorectal cancer significantly, and may be an important factor in the development of immunosuppression.
  • After getting rid of the tumor burden, the percentages of T1 and T2 increase in a short time, and the immunologic function is improved.
  • Determination of T1 may be helpful to indicate the prognosis of colorectal cancer.
  • [MeSH-major] Cell Differentiation / immunology. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology. T-Lymphocytes / cytology
  • [MeSH-minor] Aged. CD4-Positive T-Lymphocytes / cytology. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / cytology. CD8-Positive T-Lymphocytes / immunology. Female. Flow Cytometry. Humans. Killer Cells, Natural / cytology. Killer Cells, Natural / immunology. Male. Middle Aged. Neoplasm Staging. Tumor Burden

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403305.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


46. Hewitt MJ, Wood N, Quinton ND, Charlton R, Taylor G, Sheridan E, Duffy SR: The detection of microsatellite instability in blind endometrial samples--a potential novel screening tool for endometrial cancer in women from hereditary nonpolyposis colorectal cancer families? Int J Gynecol Cancer; 2006 May-Jun;16(3):1393-400
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The detection of microsatellite instability in blind endometrial samples--a potential novel screening tool for endometrial cancer in women from hereditary nonpolyposis colorectal cancer families?
  • Microsatellite instability (MSI) is the phenotypic molecular characteristic of the majority of tumors associated with the hereditary nonpolyposis colorectal cancer syndrome (HNPCC).
  • Twenty-four women with EC, 20 women from HNPCC kindreds, and 20 women undergoing gynecological surgery for benign indications underwent blind sampling.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Genomic Instability. Microsatellite Repeats
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / pathology. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / pathology. Family Health. Female. Humans. Middle Aged. Molecular Diagnostic Techniques / methods. Single-Blind Method

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803536.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Qiu MZ, Yuan ZY, Luo HY, Ruan DY, Wang ZQ, Wang FH, Li YH, Xu RH: Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumour Biol; 2010 Aug;31(4):255-60
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of pretreatment hematologic profile on survival of colorectal cancer patients.
  • Pretreatment hematologic abnormalities have been reported to have prognostic value in patients with solid tumors.
  • The aim of our study was to determine the prevalence of abnormalities in the hematologic profile in patients with colorectal cancer before treatment and to evaluate if such a profile could be used for prognostic evaluations.
  • We identified all patients in Cancer Center of Sun Yat-Sen University who were diagnosed as colorectal cancers between May 2005 and August 2009.
  • We identified 363 patients with colorectal cancer and 315 patients with benign diseases for the final analysis.
  • The percentages of leukocytosis, anemia, and thrombocytosis were significantly higher in colorectal cancer patients than in patients with benign diseases.
  • Univariate analysis showed that advanced tumor stages, leukocytosis, anemia, thrombocytosis, and low histological grade were all significantly associated with shorter survival.
  • The multivariate Cox analysis revealed that low histological grade, tumor stage, pretreatment anemia, and thrombocytosis remained independent prognostic variables for survival.
  • Anemia and thrombocytosis can be considered as useful prognostic markers in patients with colorectal cancer.
  • [MeSH-major] Anemia / diagnosis. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Leukocytosis / diagnosis. Thrombocytosis / diagnosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tex Med. 1990 Oct;86(10):80-3 [2247849.001]
  • [Cites] Clin Otolaryngol. 2008 Jun;33(3):245-51 [18559031.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2214-21 [11413508.001]
  • [Cites] Thromb Haemost. 2003 Jun;89(6):1098-106 [12783124.001]
  • [Cites] Eur Respir J. 1996 Sep;9(9):1826-30 [8880098.001]
  • [Cites] Thromb Haemost. 1998 May;79(5):916-8 [9609220.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):988-9 [15879160.001]
  • [Cites] Oncology. 2000 Feb;58(2):169-74 [10705245.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2399-405 [11745296.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1740-6 [15742330.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):2-6 [9671322.001]
  • [Cites] Urology. 2004 Mar;63(3):447-50 [15028435.001]
  • [Cites] Thromb Haemost. 1990 Dec 28;64(4):501-5 [1964750.001]
  • [Cites] Tumour Biol. 2000 Sep-Oct;21(5):309-14 [10940827.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):211-4 [14751160.001]
  • [Cites] J Am Coll Surg. 2004 May;198(5):737-41 [15110807.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):778-87 [12788185.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Dec;135(12):1783-90 [19551407.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):208-12 [17368603.001]
  • [Cites] JAMA. 1982 Feb 19;247(7):1004-6 [7035703.001]
  • [Cites] Ann Surg Oncol. 2002 Apr;9(3):287-91 [11923136.001]
  • [Cites] J Cell Mol Med. 2009 Mar;13(3):555-61 [18429933.001]
  • [Cites] J Clin Epidemiol. 1996 Dec;49(12):1373-9 [8970487.001]
  • [Cites] Oral Oncol. 2007 Mar;43(3):283-8 [16920387.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):335-42 [17504931.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):847-53 [15143932.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10 (3):295-305 [18297062.001]
  • (PMID = 20336401.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Rother T, Knöpfle E, Bohndorf K: [Virtual colonoscopy--and then? Relevance of small colorectal polyps]. Rofo; 2007 Feb;179(2):130-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Virtual colonoscopy--and then? Relevance of small colorectal polyps].
  • Colorectal carcinomas are the second most frequent malignant tumors in Germany and originate predominantly from benign polyps (adenoma-carcinoma sequence).
  • Optical colonoscopy is still the gold standard for diagnosis and treatment colorectal polyps.
  • [MeSH-major] Colonic Polyps / radiography. Colonography, Computed Tomographic. Colonoscopy. Colorectal Neoplasms / prevention & control. Intestinal Polyps / radiography

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17262241.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 42
  •  go-up   go-down


49. Chen TH, Lin CJ, Wu RC, Ho YP, Hsu CM, Lin WP, Tseng YP, Chen CH, Chiu CT: The application of miniprobe ultrasonography in the diagnosis of colorectal subepithelial lesions. Chang Gung Med J; 2010 Jul-Aug;33(4):380-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The application of miniprobe ultrasonography in the diagnosis of colorectal subepithelial lesions.
  • This study investigated the value of colonoscopic miniprobe ultrasonography for differential diagnosis and treatment strategy in patients with colorectal subepithelial lesions (SEL).
  • METHODS: Miniprobe ultrasonography was Performed in 40 consecutive patients with suspected colorectal SEL or residual lesions after endoscopic resection at one medical center by the same endoscopist (C-J Lin).
  • The final diagnosis of these lesions was confirmed by cross section imaging, histopathologic findings, or clinical follow-up.
  • RESULTS: Miniprobe EUS allowed high-resolution imaging and a successful approach to all colorectal SEL through the working channel of a sigmoidoscope or colonoscope without breakdown of the miniprobe.
  • Thirteen patients, suspected of having rectal carcinoid tumors (mean size, 6.9 +/- 3.3 mm), were treated radically by endoscopic mucosal resection using a transparent cap (EMRC) after EUS confirmation of no muscular invasion.
  • Three patients had no residual or recurrent carcinoid tumor on EUS examination after previous empiric polypectomy or biopsy.
  • Five patients had suspected rectal myogenic stromal tumors on EUS; three were transferred for surgical resection due to uterine myoma compression (N = 2) or mucinous adenocarcinoma of the appendix with rectal metastasis (N = 1), and two had uterine myoma detected by gynecologic ultrasound or CT.
  • One appendiceal stone with orifice obstruction mimicking cecal submucosal tumor was proved by surgical resection.
  • The other six patients had various benign lesions, which were diagnosed and followed-up by EUS without progression.
  • In thirty-five of forty patients (88%) colorectal SEL were managed uneventfully according to EUS interpretation.
  • CONCLUSIONS: Miniprobe ultrasonography can be a useful supplement to routine colonoscopy and provide treatment guidance for suspected colorectal subepithelial lesions.
  • [MeSH-major] Colonoscopy / methods. Colorectal Neoplasms / ultrasonography. Endosonography / methods

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20804667.001).
  • [ISSN] 2309-835X
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


50. Xi L, Gooding W, McCarty K, Godfrey TE, Hughes SJ: Identification of mRNA markers for molecular staging of lymph nodes in colorectal cancer. Clin Chem; 2006 Mar;52(3):520-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of mRNA markers for molecular staging of lymph nodes in colorectal cancer.
  • Surprisingly, no systematic analysis of potential mRNA markers for colorectal cancer has been reported.
  • We therefore performed an extensive mRNA marker survey for colorectal cancers.
  • We analyzed all markers by quantitative reverse transcription-PCR on a limited set of primary tumors and benign lymph nodes.
  • CONCLUSIONS: Several mRNA markers are capable of providing exceptionally accurate characterization of lymph node status in colorectal cancer.
  • An automated, multimarker, quantitative reverse transcription-PCR assay for characterization of lymph nodes from colorectal cancer patients may be useful for improved staging and therapeutic decision making in colorectal cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colorectal Neoplasms / diagnosis. Lymph Nodes / pathology. RNA, Messenger / analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16510433.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-01958
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


51. Shen C, Hu L, Xia L, Li Y: Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients. Jpn J Clin Oncol; 2008 Nov;38(11):770-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients.
  • OBJECTIVE: To establish a sensitive method for the early detection of circulating tumor cells (CTCs) in peripheral blood (PB) of colorectal cancer (CRC) patients.
  • METHODS: PB samples were collected from 156 CRC patients, 40 benign colorectal disease patients, 40 healthy individuals and 45 patients with other solid tumors.
  • The expression of the three mRNAs in CRC patients was significantly higher than that in benign control and healthy volunteers, and the expression of survivin and CK20 was not significantly higher than that of patients with other solid tumors.
  • However, the expression of CEA mRNA was significantly higher than that of patients with other solid tumors.
  • [MeSH-major] Carcinoembryonic Antigen / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / diagnosis. Microtubule-Associated Proteins / blood. Neoplasm Proteins / blood. Neoplastic Cells, Circulating / chemistry. RNA, Messenger / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Cell Line, Tumor. Female. Humans. Inhibitor of Apoptosis Proteins. Keratin-20 / blood. Keratin-20 / genetics. Leukocytes, Mononuclear / chemistry. Leukocytes, Mononuclear / cytology. Male. Middle Aged. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18845519.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Carcinoembryonic Antigen; 0 / Inhibitor of Apoptosis Proteins; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


52. Poultsides G, Brown M, Orlando R 3rd: Hand-assisted laparoscopic management of liver tumors. Surg Endosc; 2007 Aug;21(8):1275-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hand-assisted laparoscopic management of liver tumors.
  • METHODS: Over a 7-year period, 28 patients with liver tumors underwent 31 hand-assisted laparoscopic operations at a tertiary care center.
  • Ablation was reserved for patients with poor functional status or limited hepatic reserve, and hand-assistance was added for laparoscopic ablation of centrally located tumors (segments 7, 8, and 4a).
  • RESULTS: The selection criteria were met by 52 patients, 6 of whom had benign lesions.
  • A group of 15 patients who had metastatic colorectal cancer treated with resection and/or ablation had a mean follow-up period of 24 months (range, 2-61 months) and a mean survival time of 36 months.
  • [MeSH-major] Hepatectomy / methods. Laparoscopy / methods. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laparoendosc Surg. 1996 Mar;6 Suppl 1:S61-3 [8832930.001]
  • [Cites] Surg Endosc. 1995 Jun;9(6):733-5 [7482177.001]
  • [Cites] Surg Clin North Am. 2004 Apr;84(2):451-62 [15062655.001]
  • [Cites] Arch Surg. 2002 Apr;137(4):407-11; discussion 412 [11926943.001]
  • [Cites] J Am Coll Surg. 1999 Sep;189(3):291-9 [10472930.001]
  • [Cites] Surg Endosc. 2002 Sep;16(9):1363 [12235510.001]
  • [Cites] Br J Surg. 1993 Dec;80(12 ):1571-4 [8298929.001]
  • [Cites] Surg Endosc. 1996 Jul;10(7):758-61 [8662435.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):93-100 [9208969.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] Arch Surg. 1999 May;134(5):477-85; discussion 485-6 [10323419.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):34-43 [10631360.001]
  • [Cites] Arch Surg. 2000 Jul;135(7):854-9 [10896382.001]
  • [Cites] Arch Surg. 1997 May;132(5):505-10; discussion 511 [9161393.001]
  • [Cites] Ann Surg. 2000 May;231(5):715-23 [10767793.001]
  • (PMID = 17479339.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


53. Hassan I, Wietfeldt ED: Presacral tumors: diagnosis and management. Clin Colon Rectal Surg; 2009 May;22(2):84-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presacral tumors: diagnosis and management.
  • Presacral tumors are uncommon lesions that can be difficult to diagnose because of their nonspecific presenting signs and symptoms.
  • Surgery is the mainstay of treatment as it establishes the diagnosis and prevents the adverse consequences associated with malignant degeneration and secondary bacterial infection.
  • The outcomes for patients with benign presacral tumors are favorable.
  • Although there have been substantial improvements in the prognosis of patients with malignant presacral tumors, the development of newer adjuvant therapies are likely to further improve the oncologic outcomes of malignant presacral tumors such as chordomas and sarcomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2000 Jan;92(1 Suppl):61-70 [10616060.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):644-52 [2996861.001]
  • [Cites] Cancer Causes Control. 2001 Jan;12(1):1-11 [11227920.001]
  • [Cites] Dis Colon Rectum. 1975 Oct;18(7):581-9 [1181162.001]
  • [Cites] Tech Coloproctol. 2002 Apr;6(1):43-9 [12077641.001]
  • [Cites] Dis Colon Rectum. 1977 Sep;20(6):492-505 [143361.001]
  • [Cites] Cancer. 2004 Nov 1;101(9):2086-97 [15372471.001]
  • [Cites] Int J Colorectal Dis. 2007 Apr;22(4):381-5 [16909248.001]
  • [Cites] J Pediatr Surg. 1990 Sep;25(9):980-4 [2213451.001]
  • [Cites] Dis Colon Rectum. 1985 Nov;28(11):855-8 [4053899.001]
  • [Cites] Int J Colorectal Dis. 1993 Sep;8(3):134-8 [8245668.001]
  • [Cites] Dis Colon Rectum. 1981 Oct;24(7):501-6 [7297357.001]
  • [Cites] Surgery. 2003 May;133(5):473-8 [12773974.001]
  • [Cites] Surg Endosc. 2004 Jan;18(1):128-30 [14625743.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1581-7 [15937630.001]
  • [Cites] Dis Colon Rectum. 2005 Oct;48(10):1964-74 [15981068.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2005 Sep;15(5):302-4 [16215494.001]
  • [Cites] Onkologie. 2006 Dec;29(12):572-4 [17202828.001]
  • [Cites] Curr Opin Oncol. 2007 Jul;19(4):367-70 [17545801.001]
  • [Cites] Br J Surg. 2008 Feb;95(2):214-21 [17933000.001]
  • [Cites] J Minim Invasive Gynecol. 2008 Sep-Oct;15(5):649-51 [18722980.001]
  • [Cites] Orthop Clin North Am. 2009 Jan;40(1):105-23, vii [19064059.001]
  • [Cites] Dis Colon Rectum. 1996 Oct;39(10):1176-9 [8831537.001]
  • [Cites] Cancer. 2000 May 1;88(9):2122-34 [10813725.001]
  • (PMID = 20436832.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780241
  • [Keywords] NOTNLM ; Presacral tumors / diagnosis / management / prognosis / surgery
  •  go-up   go-down


54. Campos FG, Valarini R: Evolution of laparoscopic colorectal surgery in Brazil: results of 4744 patients from the national registry. Surg Laparosc Endosc Percutan Tech; 2009 Jun;19(3):249-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution of laparoscopic colorectal surgery in Brazil: results of 4744 patients from the national registry.
  • BACKGROUND: Since its introduction, laparoscopic colorectal surgery has raised intense debate and controversies regarding its safety and effectiveness.
  • METHODS: This multicentric registry reports the experience of 28 Brazilian surgical teams specializing in laparoscopic colorectal surgery.
  • Benign diseases were diagnosed in 2356 patients (49.6%).
  • Two thousand three hundred and eighty-nine (50.4%) malignant tumors were operated upon, and histologic classification showed 2347 (98%) adenocarcinomas, 30 (0.6%) spinocelular carcinomas, and 12 (0.2%) other histologic types.
  • Tumor recurrence rate was 16.3% among patients followed more than 1 year.
  • Compared with other registries, there was a 75% increase in the number of groups performing laparoscopic colorectal surgery and a decrease in conversions (from 10.5% to 5.5%) and mortality (from 1.5% to 0.9%) rates.
  • (2) operative indications for benign and malignant diseases were similar, and diverticular disease of the colon comprised 40% of the benign ones;.

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542856.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Glasgow SC, Dietz DW: Retrorectal tumors. Clin Colon Rectal Surg; 2006 May;19(2):61-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrorectal tumors.
  • Primary neoplasms of the retrorectal (presacral) space are very rare.
  • These lesions may be congenital or acquired, benign or malignant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1581-7 [15937630.001]
  • [Cites] Ann Surg. 1942 Mar;115(3):378-89 [17857980.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1198-202 [10506704.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):251-5 [9500228.001]
  • [Cites] Dis Colon Rectum. 1996 Aug;39(8):938-42 [8756852.001]
  • [Cites] Int J Colorectal Dis. 1993 Sep;8(3):134-8 [8245668.001]
  • [Cites] Dis Colon Rectum. 1988 Oct;31(10):806-7 [3168668.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):644-52 [2996861.001]
  • [Cites] Radiology. 1986 Mar;158(3):839-43 [3945761.001]
  • [Cites] Dis Colon Rectum. 1985 Nov;28(11):855-8 [4053899.001]
  • [Cites] J R Soc Med. 1990 Mar;83(3):185-7 [2157842.001]
  • [Cites] Dis Colon Rectum. 1981 Oct;24(7):501-6 [7297357.001]
  • [Cites] Dis Colon Rectum. 1977 Sep;20(6):492-505 [143361.001]
  • [Cites] JAMA. 1977 Jan 3;237(1):39-42 [576128.001]
  • [Cites] Dis Colon Rectum. 1975 Oct;18(7):581-9 [1181162.001]
  • [Cites] Surg Gynecol Obstet. 1971 Apr;132(4):681-6 [4995717.001]
  • [Cites] Br Med J. 1969 Feb 15;1(5641):420-2 [4884653.001]
  • [Cites] Am J Surg. 1976 Sep;132(3):377-83 [786055.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):880-6 [12788424.001]
  • [Cites] Surgery. 2003 May;133(5):473-8 [12773974.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):291-6 [12679315.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):411-3 [12626920.001]
  • [Cites] Ann Surg. 1964 Jun;159:911-8 [14170292.001]
  • (PMID = 20011312.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780106
  • [Keywords] NOTNLM ; Retrorectal tumors / chordoma / presacral space / teratoma
  •  go-up   go-down


56. Wong SC, Chan CM, Ma BB, Hui EP, Ng SS, Lai PB, Cheung MT, Lo ES, Chan AK, Lam MY, Au TC, Chan AT: Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res; 2009 Feb 1;15(3):1005-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients.
  • PURPOSE: Current immunomagnetic enrichment method can only detect general epithelial antigens of circulating tumor cells (CTC).
  • Further characterization of the CTCs to provide specific information on the tumor type is not possible.
  • We attempted to overcome this drawback by developing the methodology for using a gastrointestinal-specific anti-cytokeratin (CK) 20 antibody to detect CTCs in colorectal cancer patients' blood.
  • EXPERIMENTAL DESIGN: The protocol was validated using a colorectal cancer SW480 cell line.
  • The clinical significance of findings in colorectal cancer was investigated by detecting CK20-positive CTCs (pCTC) in patients with colorectal cancer, other common cancers, colorectal adenoma, benign colorectal diseases, and normal subjects.
  • Moreover, the malignant nature of CK20 pCTCs was examined by comparing chromosome 17 aberration patterns with those from the corresponding primary tumors.
  • When applied in patient samples, the detection rates were 62% (132 colorectal cancer patients; median number = 11 CTCs), 0% (120 patients with other common cancers), 6% (50 colorectal adenoma patients), 0% (120 patients with benign colorectal diseases), and 0% (40 normal subjects).
  • Furthermore, statistical analysis showed that CK20 pCTC numbers were associated with tumor-node-metastasis stage and lymph node status.
  • Using the median CK20 pCTC numbers as the cutoff points, stratified groups of colorectal cancer patients had significant differences in their recurrence, metastasis, and survival.
  • Finally, chromosome 17 aneusomy in 90% of colorectal cancer patients with CK20 pCTCs matched with those from the primary tumors.
  • CONCLUSIONS: Detection of CK20 pCTCs using the new protocol could generate clinically important information for colorectal cancer patients.
  • [MeSH-major] Colorectal Neoplasms / blood. Immunomagnetic Separation / methods. Keratin-20 / blood. Neoplastic Cells, Circulating / chemistry
  • [MeSH-minor] Adenoma / blood. Biomarkers, Tumor / blood. Cell Line, Tumor. Chromosomes, Human, Pair 17. Humans. Prognosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188172.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20
  •  go-up   go-down


57. Chang X, Han J, Pang L, Zhao Y, Yang Y, Shen Z: Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer; 2009;9:40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased PADI4 expression in blood and tissues of patients with malignant tumors.
  • METHODS: Expression of PADI4 was investigated in various tumors and non-tumor tissues (n = 1673) as well as in A549, SKOV3 and U937 tumor cell lines by immunohistochemistry, real-time PCR, and western blot.
  • Levels of PADI4 and citrullinated antithrombin (cAT) were investigated in the blood of patients with various tumors by ELISA (n = 1121).
  • RESULTS: Immunohistochemistry detected significant PADI4 expression in various malignancies including breast carcinomas, lung adenocarcinomas, hepatocellular carcinomas, esophageal squamous cancer cells, colorectal adenocarcinomas, renal cancer cells, ovarian adenocarcinomas, endometrial carcinomas, uterine adenocarcinomas, bladder carcinomas, chondromas, as well as other metastatic carcinomas.
  • However, PADI4 expression was not observed in benign leiomyomas of stomach, uterine myomas, endometrial hyperplasias, cervical polyps, teratomas, hydatidiform moles, trophoblastic cell hyperplasias, hyroid adenomas, hemangiomas, lymph hyperplasias, schwannomas, neurofibromas, lipomas, and cavernous hemangiomas of the liver.
  • Additionally, PADI4 expression was not detected in non-tumor tissues including cholecystitis, cervicitis and synovitis of osteoarthritis, except in certain acutely inflamed tissues such as in gastritis and appendicitis.
  • Furthermore, western blot analysis detected PADI4 expression in cultured tumor cell lines.
  • ELISA detected increased PADI4 and cAT levels in the blood of patients with various malignant tumors compared to those in patients with chronic inflammation and benign tumors.
  • Additionally, PADI4 and cAT levels were significantly associated with higher levels of known tumor markers.
  • CONCLUSION: Our results suggest that PADI4 expression is increased in the blood and tissues of many malignant tumors, a finding useful for further understanding of tumorigenesis.
  • [MeSH-major] Hydrolases / metabolism. Neoplasm Proteins / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Antithrombins / metabolism. Blotting, Western. Cell Line, Tumor. Citrulline / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Immunoprecipitation. Male. Polymerase Chain Reaction / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 1998 May-Jun;84(3):364-7 [9678618.001]
  • [Cites] Pathologe. 1996 Nov;17(6):425-32 [9082363.001]
  • [Cites] J Cell Mol Med. 2004 Oct-Dec;8(4):498-508 [15601578.001]
  • [Cites] Folia Histochem Cytobiol. 2004;42(4):235-40 [15704650.001]
  • [Cites] Rheumatology (Oxford). 2005 Mar;44(3):293-8 [15561738.001]
  • [Cites] Semin Cancer Biol. 2005 Aug;15(4):309-18 [15907383.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2936-42 [16365013.001]
  • [Cites] Mol Carcinog. 2006 Mar;45(3):183-96 [16355400.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1261-9 [16799479.001]
  • [Cites] Mol Endocrinol. 2007 Jul;21(7):1617-29 [17456793.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):76-80 [17826626.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1682-9 [18350599.001]
  • [Cites] Histochem Cell Biol. 2008 Jun;129(6):705-33 [18461349.001]
  • [Cites] Endocr Relat Cancer. 2008 Jun;15(2):475-83 [18509000.001]
  • [Cites] J Biol Chem. 2008 Jul 18;283(29):20060-8 [18499678.001]
  • [Cites] Mol Cell Biol. 2008 Aug;28(15):4745-58 [18505818.001]
  • [Cites] Adv Exp Med Biol. 2008;630:112-32 [18637488.001]
  • [Cites] Histopathology. 2001 Jan;38(1):62-7 [11135048.001]
  • [Cites] Cell Death Differ. 2002 May;9(5):486-92 [11973607.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):173-7 [12023846.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):201-7 [12023851.001]
  • [Cites] Nat Genet. 2003 Aug;34(4):395-402 [12833157.001]
  • [Cites] Best Pract Res Clin Anaesthesiol. 2004 Sep;18(3):385-405 [15212335.001]
  • [Cites] Cell. 2004 Sep 3;118(5):545-53 [15339660.001]
  • [Cites] Anticancer Res. 1990 May-Jun;10(3):579-82 [2114816.001]
  • [Cites] APMIS. 1991 Nov;99(11):981-8 [1720319.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(3):209-15 [1384221.001]
  • [Cites] Int J Cancer. 1993 Jul 9;54(5):793-806 [7686887.001]
  • [Cites] Thromb Haemost. 1998 Nov;80(5):767-72 [9843169.001]
  • (PMID = 19183436.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antithrombins; 0 / Neoplasm Proteins; 29VT07BGDA / Citrulline; EC 3.- / Hydrolases; EC 3.5.3.15 / peptidylarginine deiminase type IV
  • [Other-IDs] NLM/ PMC2637889
  •  go-up   go-down


58. Satgé D, Sasco AJ, Vekemans MJ, Portal ML, Fléjou JF: Aspects of digestive tract tumors in Down syndrome: a literature review. Dig Dis Sci; 2006 Nov;51(11):2053-61
MedlinePlus Health Information. consumer health - Down Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aspects of digestive tract tumors in Down syndrome: a literature review.
  • The purpose of this study was to describe the digestive neoplasms found in persons with Down syndrome.
  • Due to intellectual disability, persons with Down syndrome do not convey their symptoms and pain, leading to delayed diagnosis and potentially worse outcome.
  • It is thus important to know which organs are at risk for tumors and possible tumor risk factors.
  • In a review of the literature, we found 13 benign tumors and 127 cancers in 1 fetus, 8 children, and 131 adults with Down syndrome.
  • The review suggests a decreased incidence of digestive cancer, however, with a possible increased incidence of neoplasms of the pancreas and gallbladder.
  • This review may allow a more specific, adapted medical follow-up for persons with Down syndrome and could help to elucidate the oncogenesis of digestive neoplasms.
  • [MeSH-major] Digestive System Neoplasms / epidemiology. Down Syndrome / epidemiology
  • [MeSH-minor] Colorectal Neoplasms / epidemiology. Comorbidity. Esophageal Neoplasms / epidemiology. Incidence. Liver Neoplasms / epidemiology. Oropharyngeal Neoplasms / epidemiology. Pancreatic Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Jan 15;355(9199):165-9 [10675114.001]
  • [Cites] Lancet. 1997 Feb 15;349(9050):485-9 [9040589.001]
  • [Cites] Acta Paediatr. 1998 Dec;87(12):1307-9 [9894836.001]
  • [Cites] J Nutr. 2000 Feb;130(2):129-32 [10720158.001]
  • [Cites] Oncogene. 1998 May;16(20):2687-93 [9632145.001]
  • [Cites] J Intellect Disabil Res. 1993 Dec;37 ( Pt 6):543-51 [8124000.001]
  • [Cites] Science. 1997 Nov 21;278(5342):1464-6 [9367959.001]
  • [Cites] Int J Oncol. 2000 Aug;17(2):245-52 [10891531.001]
  • [Cites] Cancer Causes Control. 2004 Dec;15(10):1021-5 [15801486.001]
  • [Cites] Arch Dis Child. 2004 Nov;89(11):1014-7 [15499053.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):599-612 [6295193.001]
  • [Cites] J Am Diet Assoc. 1996 Dec;96(12):1262-7 [8948387.001]
  • [Cites] Dev Med Child Neurol. 1982 Dec;24(6):817-29 [6218002.001]
  • [Cites] Prog Pediatr Surg. 1977;10:33-4 [141055.001]
  • [Cites] J Intellect Disabil Res. 1997 Aug;41 ( Pt 4):312-6 [9297608.001]
  • [Cites] Am J Med Genet. 1993 Jun 15;46(5):612 [8322833.001]
  • [Cites] J Ment Defic Res. 1989 Apr;33 ( Pt 2):185-7 [2542562.001]
  • [Cites] J Am Acad Dermatol. 1991 Nov;25(5 Pt 2):909-11 [1837034.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Oct-Nov;20(7):517-29 [12959856.001]
  • [Cites] J Oral Maxillofac Surg. 1992 Oct;50(10):1087-90 [1388203.001]
  • [Cites] Ned Tijdschr Geneeskd. 1996 Oct 19;140(42):2083-7 [8965950.001]
  • [Cites] J Biol Chem. 1998 Jul 24;273(30):18871-80 [9668063.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Apr;18(4):318-21 [9087574.001]
  • [Cites] Hum Genet. 1989 Jun;82(3):291-2 [2525108.001]
  • [Cites] Langenbecks Arch Surg. 2001 Apr;386(3):224-9 [11382326.001]
  • [Cites] Cancer. 2002 Nov 1;95(9):1946-53 [12404289.001]
  • [Cites] J Intellect Disabil Res. 2001 Jun;45(Pt 3):219-25 [11422646.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Dec;26(4):312-21 [10534766.001]
  • [Cites] J Postgrad Med. 1998 Jan-Mar;44(1):16-8 [10703561.001]
  • [Cites] Downs Syndr Res Pract. 2002 Mar;8(1):31-6 [11915436.001]
  • [Cites] Tumori. 2003 Mar-Apr;89(2):193-5 [12841670.001]
  • [Cites] Int J Cancer. 2001 Sep 1;93(5):741-4 [11477589.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1997 Jun;9(6):589-92 [9222731.001]
  • [Cites] Cancer Genet Cytogenet. 2005 May;159(1):37-43 [15860355.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jan;21(1):1 [9443035.001]
  • [Cites] Int J Cancer. 2001 Feb 1;91(3):350-8 [11169959.001]
  • [Cites] Arch Intern Med. 2003 Mar 24;163(6):705-11 [12639204.001]
  • [Cites] Mil Med. 1995 Sep;160(9):477-9 [7478037.001]
  • [Cites] Lancet. 2000 Dec 2;356(9245):1882-7 [11130384.001]
  • [Cites] Science. 1996 Oct 11;274(5285):259-62 [8824193.001]
  • [Cites] J Natl Cancer Inst. 1968 May;40(5):1087-99 [5648134.001]
  • [Cites] Lancet. 2001 Aug 4;358(9279):356-61 [11502314.001]
  • [Cites] Lancet. 2003 Apr 12;361(9365):1281-9 [12699967.001]
  • [Cites] Ann Hum Genet. 2001 Mar;65(Pt 2):167-76 [11427176.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] J Pediatr Surg. 1998 Sep;33(9):1380-2 [9766358.001]
  • [Cites] Arch Dis Child. 2001 Sep;85(3):242-3 [11517110.001]
  • [Cites] J Intellect Disabil Res. 2001 Aug;45(Pt 4):300-7 [11489051.001]
  • [Cites] Cancer Lett. 2003 Oct 8;200(1):25-31 [14550949.001]
  • [Cites] Dev Med Child Neurol. 2000 Oct;42(10):691-8 [11085298.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):205-8 [12532432.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Jan;18(1):59-65 [8993981.001]
  • [Cites] Eur J Pediatr. 1997 May;156(5):420-1 [9177993.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1198-205 [8108387.001]
  • [Cites] Br J Radiol. 1995 Jan;68(805):85-8 [7881890.001]
  • [Cites] Bristol Med Chir J. 1977 Jan-Apr;92(341-342):3-7 [612362.001]
  • [Cites] Acta Paediatr Scand. 1975 Mar;64(2):322-6 [124122.001]
  • [Cites] J Intellect Disabil Res. 1994 Feb;38 ( Pt 1):9-26 [8173229.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7375-8 [11606364.001]
  • [Cites] Acta Paediatr. 1999 Sep;88(9):953-6 [10519335.001]
  • [Cites] Am J Gastroenterol. 1997 Jun;92(6):1000-4 [9177519.001]
  • [Cites] Science. 2004 Oct 22;306(5696):687-90 [15499018.001]
  • [Cites] Am J Med Genet. 1998 Jul 7;78(3):207-16 [9677053.001]
  • [Cites] Br J Cancer. 1962 Jun;16:177-86 [13908377.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Jul;10(3):177-82 [7522040.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):88-95 [11391481.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1974 Feb;37(2):202-7 [4272495.001]
  • [Cites] Acta Paediatr. 1995 Jun;84(6):711-2 [7670266.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):168-70 [15386432.001]
  • [Cites] Cesk Gastroenterol Vyz. 1975 Jun;29(4):275-7 [124229.001]
  • [Cites] Br J Psychiatry. 1990 Apr;156:531-3 [2143684.001]
  • [Cites] Br J Radiol. 1975 Jan;48(565):16-8 [1109621.001]
  • [Cites] J Clin Gastroenterol. 1986 Apr;8(2):111-4 [2943789.001]
  • [Cites] J Thorac Cardiovasc Surg. 1976 Aug;72(2):315-8 [134182.001]
  • [Cites] Oncol Rep. 1999 Nov-Dec;6(6):1223-7 [10523685.001]
  • [Cites] Am J Ment Retard. 1991 Jan;95(4):397-403 [2003909.001]
  • [Cites] Am J Gastroenterol. 2001 Jun;96(6):1718-24 [11419820.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2004 Aug;39(2):187-91 [15269626.001]
  • [Cites] Cancer Lett. 2000 Oct 16;159(1):15-21 [10974401.001]
  • [Cites] Am J Med Genet. 1998 Jun 5;77(5):431-8 [9632176.001]
  • [Cites] Paediatr Perinat Epidemiol. 2000 Oct;14(4):372 [11101025.001]
  • [Cites] J Interferon Res. 1990 Oct;10(5):515-7 [2148760.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1019-25 [11937181.001]
  • [Cites] Am Fam Physician. 1997 Aug;56(2):485-94 [9262529.001]
  • [Cites] Surg Today. 1998;28(5):567-9 [9607913.001]
  • [Cites] Eur J Hum Genet. 2001 Nov;9(11):811-4 [11781696.001]
  • (PMID = 17009117.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 103
  •  go-up   go-down


59. Hall PA, Todd CB, Hyland PL, McDade SS, Grabsch H, Dattani M, Hillan KJ, Russell SE: The septin-binding protein anillin is overexpressed in diverse human tumors. Clin Cancer Res; 2005 Oct 1;11(19 Pt 1):6780-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The septin-binding protein anillin is overexpressed in diverse human tumors.
  • The median level of anillin mRNA expression was higher in tumors than normal tissues (median fold increase 2.58; 95% confidence intervals, 2.19-5.68, P < 0.0001) except in the central nervous system where anillin mRNA levels were lower in tumors.
  • Anillin mRNA expression was analyzed during tumor progression in breast, ovarian, kidney, colorectal, hepatic, lung, endometrial, and pancreatic tumors and in all tissues there was progressive increase in anillin mRNA expression from normal to benign to malignant to metastatic disease.
  • Thus, anillin is overexpressed in diverse common human tumors, but not simply as a consequence of being a proliferation marker.
  • [MeSH-major] Contractile Proteins / chemistry. Contractile Proteins / physiology. Cytoskeletal Proteins / metabolism. Gene Expression Regulation, Neoplastic. Neoplasms / metabolism
  • [MeSH-minor] Actins / metabolism. Biomarkers, Tumor. Blotting, Northern. Cell Cycle Proteins / metabolism. Cell Line, Tumor. Cell Nucleus / metabolism. Central Nervous System / embryology. Cloning, Molecular. DNA, Complementary / metabolism. Exons. HeLa Cells. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Microfilament Proteins / metabolism. Mitochondrial Proteins / metabolism. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction. Protein Binding. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Distribution. Transcription, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203764.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Contractile Proteins; 0 / Cytoskeletal Proteins; 0 / DNA, Complementary; 0 / Ki-67 Antigen; 0 / Microfilament Proteins; 0 / Mitochondrial Proteins; 0 / RNA, Messenger; 0 / anillin
  •  go-up   go-down


60. Shi X, Gong E, Wu X: Alpha-methylacyl-CoA racemase/P504S overexpression in colorectal carcinoma is correlated with tumor differentiation. Appl Immunohistochem Mol Morphol; 2007 Jun;15(2):175-80
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-methylacyl-CoA racemase/P504S overexpression in colorectal carcinoma is correlated with tumor differentiation.
  • Little is known about correlation of AMACR expression with colorectal carcinoma (CRC) differentiation and prognosis.
  • These cases were divided into 3 groups according to the histologic differentiation of the primary tumors. group A included 50 cases of histologically well and moderately differentiated CRCs, 20 of these with lymph node metastasis; group B included 23 cases of well and moderately differentiated CRCs, histologically similar to group A, except these tumors had small foci (less than 20%) of high-grade carcinoma, and 10 of these had lymph node metastasis; group C included 33 cases of poorly differentiated adenocarcinoma and undifferentiated carcinoma, 17 with lymph node metastasis.
  • In group B, although overexpression of AMACR in primary tumors was similar to that of group A, it was only seen in 30.0% of group B metastatic tumors, which was similar to the rate of expression in group C (23.5%).
  • In contrast, rates of expression in group A primary and metastatic tumors were similar (80.0% and 75.0%).
  • Positive staining for AMACR in benign epithelium adjacent to tumor was rare (<2%).
  • Our findings support the view that the expression of AMACR in CRC is correlated with tumor differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525630.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


61. Amegbor K, Napo-Koura GA, Songne-Gnamkoulamba B, Redah D, Tekou A: Epidemiological and pathological aspects of gastrointestinal tumors in Togo. Gastroenterol Clin Biol; 2008 Apr;32(4):430-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiological and pathological aspects of gastrointestinal tumors in Togo.
  • PURPOSE: The incidence of gastrointestinal tumors is difficult to estimate in Togo, so the purpose of this report was to describe the tumors diagnosed by the national pathology laboratory.
  • METHODS: This was a retrospective descriptive study of 742 gastrointestinal tumors diagnosed between 1986 and 2005 by the pathology laboratory of the Tokoin university hospital in Lomé, Togo.
  • RESULTS: There was an annual incidence of 37 gastrointestinal tumors, including 27 cancers, with twice as many tumors diagnosed in men as in women.
  • The average age of patients diagnosed with a benign tumor was 44 years compared with 52 years for those with a malignant tumor.
  • Stomach tumors predominated (n=306; 41.2%).
  • Papilloma was the most frequent benign tumor type (n=100; 47.8%), while malignant tumors were mostly gastric adenocarcinoma (n=224; 42% of all cancers), esophageal squamous cell carcinoma (n=100; 19%) and colorectal adenocarcinoma (n=89; 17%).
  • CONCLUSION: Gastrointestinal tumors are frequently seen in Togo, and an epidemiological monitoring program is needed.
  • [MeSH-major] Gastrointestinal Neoplasms / epidemiology. Gastrointestinal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18359594.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


62. Li FY, Ren XB, Xu EP, Huang Q, Sheng HQ, Lv BJ, Lai MD: RegIV expression showing specificity to gastrointestinal tract and its potential role in diagnosing digestive tract neuroendocrine tumor. J Zhejiang Univ Sci B; 2010 Apr;11(4):258-66
Genetic Alliance. consumer health - Pancreatic islet cell tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RegIV expression showing specificity to gastrointestinal tract and its potential role in diagnosing digestive tract neuroendocrine tumor.
  • To learn more about RegIV, we evaluated its distribution by immunohistochemistry (IHC) in a total of 360 samples including 24 types of normal tissue, 40 benign and malignant lesions, and 18 neuroendocrine tumors.
  • Studies on additional sets of colorectal tumor samples showed that RegIV expression was predominant in colorectal adenoma (87.5%) and peritumoral tissue (100%) but not in cancer tissue (30.8%).
  • Among neuroendocrine tumors, RegIV had a relatively restricted expression to those of digestive system.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Gastrointestinal Tract / metabolism. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Lectins, C-Type / biosynthesis. Neuroendocrine Tumors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Feb;13(2):140-6 [10697270.001]
  • [Cites] Hum Pathol. 2010 Jan;41(1):59-69 [19740514.001]
  • [Cites] Biochim Biophys Acta. 2001 Apr 16;1518(3):287-93 [11311942.001]
  • [Cites] Diabetes. 2002 Feb;51(2):339-46 [11812740.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):185-93 [12455032.001]
  • [Cites] Am J Pathol. 2003 Jul;163(1):11-20 [12819006.001]
  • [Cites] Cancer Lett. 2003 Oct 8;200(1):69-76 [14550954.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):963-9 [14559978.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2635-41 [14669303.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1130-6 [15022278.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3694-700 [15150130.001]
  • [Cites] J Am Coll Surg. 1994 Aug;179(2):231-48 [8044398.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2237-43 [15788672.001]
  • [Cites] J Pathol. 2005 Oct;207(2):185-98 [16086444.001]
  • [Cites] Gut. 2005 Oct;54(10):1437-44 [15914572.001]
  • [Cites] Gastroenterology. 2006 Jan;130(1):137-49 [16401477.001]
  • [Cites] Cancer Sci. 2006 Nov;97(11):1191-7 [16918991.001]
  • [Cites] Cancer Biol Ther. 2006 Dec;5(12):1714-20 [17106246.001]
  • [Cites] Lab Invest. 2007 Mar;87(3):304-14 [17260007.001]
  • [Cites] Oncology. 2007;72(5-6):371-80 [18187959.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3063-72 [18565894.001]
  • [ErratumIn] J Zhejiang Univ Sci B. 2010 May;11(5):390
  • (PMID = 20349522.001).
  • [ISSN] 1862-1783
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / REG4 protein, human
  • [Other-IDs] NLM/ PMC2852542
  •  go-up   go-down


63. Zheng JP, Shao GL, Chen YT, Fan SF, Yang JM: [Feasibility study on CT guided percutaneous incisional needle biopsy for deep pelvic masses by different puncture approaches]. Zhonghua Zhong Liu Za Zhi; 2009 Oct;31(10):786-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-four malignant lesions were confirmed by pathology, including 30 adenocarcinomas, 19 squamous cell carcinomas, 5 unclassified malignant tumors, 3 small cell carcinomas, 2 malignant giant cell tumors of bone, 2 hepatocellular carcinomas and 3 false negative lesions which were confirmed at the second PINBs as malignant tumors, respectively.
  • Benign neoplasms were confirmed in 8 cases, including fibrosis tissue in 6 lesions, bone tuberculosis in 1 and ovarian cyst in 1.
  • No hematoma, nerve damage, infection, and tumor transplantation in pelvic cavity developed after the PINB procedure.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle / methods. Carcinoma, Squamous Cell / pathology. Pelvic Neoplasms / pathology. Pelvis / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colorectal Neoplasms / pathology. Colorectal Neoplasms / radiography. Diagnosis, Computer-Assisted / methods. Feasibility Studies. Female. Fibrosis / pathology. Fibrosis / radiography. Follow-Up Studies. Humans. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Male. Middle Aged. Tomography, X-Ray Computed. Uterine Neoplasms / pathology. Uterine Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021836.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


64. Nguyen KT, Gamblin TC, Geller DA: World review of laparoscopic liver resection-2,804 patients. Ann Surg; 2009 Nov;250(5):831-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY BACKGROUND DATA: Initially described for peripheral, benign tumors resected by nonanatomic wedge resections, minimally invasive liver resections are now being performed more frequently, even for larger, malignant tumors located in challenging locations.
  • Tumor type, operative characteristics, perioperative morbidity, and oncologic outcomes were tabulated.
  • Fifty percent were for malignant tumors, 45% were for benign lesions, 1.7% were for live donor hepatectomies, and the rest were indeterminate.
  • The 3-year overall and disease-free survival rates after laparoscopic liver resection for colorectal metastasis to the liver were 80% to 87% and 51%, respectively.
  • Oncologically, 3- and 5-year survival rates reported for hepatocellular carcinoma and colorectal cancer metastases are comparable to open hepatic resection, albeit in a selected group of patients.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2015 Aug;262(2):e77-8 [24509191.001]
  • [CommentIn] Ann Surg. 2015 Aug;262(2):e78 [24670850.001]
  • (PMID = 19801936.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 114
  •  go-up   go-down


65. Cho JY, Han HS, Yoon YS, Shin SH: Outcomes of laparoscopic liver resection for lesions located in the right side of the liver. Arch Surg; 2009 Jan;144(1):25-9
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overall, data from 40 patients with benign liver tumors (n = 2), intrahepatic duct stones (n = 3), liver metastasis from colorectal cancer (n = 8), and hepatocellular carcinomas (n = 27) were analyzed.
  • [MeSH-major] Hepatectomy / methods. Laparoscopy. Liver Diseases / pathology. Liver Diseases / surgery. Liver Neoplasms / pathology. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19153321.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Buell JF, Thomas MT, Rudich S, Marvin M, Nagubandi R, Ravindra KV, Brock G, McMasters KM: Experience with more than 500 minimally invasive hepatic procedures. Ann Surg; 2008 Sep;248(3):475-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We retrospectively reviewed all patients who underwent a minimally invasive procedure for the management of hepatic tumors between January 2001 and April 2008.
  • To compare the various forms of surgery, we analyzed the incidence of complications, tumor recurrence, mortality, and cost.
  • The representative tumor histologies were: hepatocellular carcinoma (HCC; N = 210), colorectal carcinoma (N = 40), miscellaneous liver metastases (N = 42), biliary cancer (N = 20), and benign tumors (N = 176).
  • Our present data are equivalent or superior to those encountered in any large open series.
  • This series confirmed excellent interim survival rates after laparoscopic HR and superiority over RFA in the treatment of cancer, with significantly lower local tumor recurrence rate.
  • [MeSH-major] Hepatectomy / statistics & numerical data. Liver Neoplasms / surgery. Minimally Invasive Surgical Procedures / statistics & numerical data
  • [MeSH-minor] Catheter Ablation / statistics & numerical data. Humans. Laparoscopy / statistics & numerical data. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Ultrasonography / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2009 Jun;249(6):1064-5; author reply 1065-6 [19474661.001]
  • (PMID = 18791368.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Groen EJ, Roos A, Muntinghe FL, Enting RH, de Vries J, Kleibeuker JH, Witjes MJ, Links TP, van Beek AP: Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol; 2008 Sep;15(9):2439-50
Genetic Alliance. consumer health - Familial Polyposis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Familial adenomatous polyposis (FAP) is an autosomal dominantly inherited disorder, which results from a germ line mutation in the APC (adenomatous polyposis coli) gene.
  • FAP is characterized by the formation of hundreds to thousands of colorectal adenomatous polyps.
  • Although the development of colorectal cancer stands out as the most prevalent complication, FAP is a multisystem disorder of growth.
  • Affected individuals can develop thyroid and pancreatic cancer, hepatoblastomas, CNS tumors (especially medulloblastomas), and various benign tumors such as adrenal adenomas, osteomas, desmoid tumors and dental abnormalities.
  • Due to improved longevity, as a result of better prevention of colorectal cancer, the risk of these clinical problems will further increase.
  • [MeSH-major] Adenomatous Polyposis Coli / diagnosis. Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 May;18(9):1967-79 [10784639.001]
  • [Cites] Mayo Clin Proc. 2000 Jun;75(6):636-7 [10852426.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21 Suppl):81S-92S [11060333.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1739-42 [11156460.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1759-62; discussion 1762-3 [11156464.001]
  • [Cites] Endocr Res. 2000 Nov;26(4):783-90 [11196455.001]
  • [Cites] Int J Cancer. 2001 Mar 20;95(2):102-7 [11241320.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):721-33 [11257105.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):429-32 [11283619.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2744-58 [9215849.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):465-72 [9242755.001]
  • [Cites] Intern Med. 1997 Aug;36(8):536-42 [9260769.001]
  • [Cites] Int J Colorectal Dis. 1997;12(4):240-2 [9272455.001]
  • [Cites] Dis Colon Rectum. 1997 Sep;40(9):1023-8 [9293929.001]
  • [Cites] Gut. 1997 Sep;41(3):417 [9378405.001]
  • [Cites] Int J Cancer. 1998 Jan 5;75(1):162-4 [9426707.001]
  • [Cites] Ann Surg. 1998 Jan;227(1):57-62 [9445111.001]
  • [Cites] Hum Pathol. 1998 Mar;29(3):302-6 [9496836.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):286-92 [10634400.001]
  • [Cites] Scand J Gastroenterol. 1999 Dec;34(12):1230-5 [10636071.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):433-8 [11283620.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):332-9 [11466687.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1127-35 [11677205.001]
  • [Cites] Am J Gastroenterol. 2002 Jan;97(1):180-5 [11808944.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):55-67 [11900252.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):1941-6 [11994321.001]
  • [Cites] Gut. 2002 Sep;51(3):446-9 [12171972.001]
  • [Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]
  • [Cites] Gut. 2003 May;52(5):742-6 [12692062.001]
  • [Cites] Acta Radiol. 2003 Mar;44(2):158-9 [12694100.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1698-707 [12721244.001]
  • [Cites] Lancet. 2003 May 3;361(9368):1552-4 [12737880.001]
  • [Cites] Lancet. 2003 Jun 14;361(9374):2059-67 [12814730.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):668-78 [12910509.001]
  • [Cites] Eur J Cancer. 2003 Oct;39(15):2200-4 [14522379.001]
  • [Cites] Fam Cancer. 2001;1(2):111-9 [14574007.001]
  • [Cites] Gastroenterol Clin Biol. 2003 Aug-Sep;27(8-9):818-20 [14586255.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):612-20 [14745880.001]
  • [Cites] Semin Neonatol. 2003 Oct;8(5):403-10 [15001128.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):652; author reply 653 [15274082.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):666-75 [15497120.001]
  • [Cites] Australas Ann Med. 1967 Aug;16(3):242-4 [6056613.001]
  • [Cites] Clin Genet. 1981 Jul;20(1):67-73 [7296952.001]
  • [Cites] Cancer. 1983 Mar 15;51(6):1171-5 [6129922.001]
  • [Cites] Arch Dis Child. 1983 Dec;58(12):959-62 [6318669.001]
  • [Cites] Cancer. 1985 May 1;55(9):2001-4 [3978580.001]
  • [Cites] Dis Colon Rectum. 1986 Jan;29(1):55-8 [3940808.001]
  • [Cites] N Engl J Med. 1987 Mar 12;316(11):661-7 [3821797.001]
  • [Cites] Br J Surg. 1987 May;74(5):377-80 [3036290.001]
  • [Cites] Acta Chir Scand. 1987;153(5-6):379-83 [2821714.001]
  • [Cites] Med Pediatr Oncol. 1989;17(5):441-7 [2571918.001]
  • [Cites] J Craniomaxillofac Surg. 1989 Nov;17(8):350-3 [2592575.001]
  • [Cites] J Pediatr. 1991 Nov;119(5):766-8 [1658283.001]
  • [Cites] Surgery. 1991 Dec;110(6):1014-21 [1745970.001]
  • [Cites] Hum Genet. 1992 May;89(3):298-300 [1351034.001]
  • [Cites] Am J Med Genet. 1992 Aug 1;43(6):1023-5 [1329510.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):101-8 [8382467.001]
  • [Cites] Int J Oral Maxillofac Surg. 1993 Aug;22(4):226-30 [8409564.001]
  • [Cites] Dis Colon Rectum. 1993 Nov;36(11):1059-62 [8223060.001]
  • [Cites] Gastroenterology. 1993 Nov;105(5):1550-2 [8224661.001]
  • [Cites] Gut. 1993 Oct;34(10):1394-6 [8244108.001]
  • [Cites] Gut. 1994 Mar;35(3):377-81 [8150351.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2065-8 [8156512.001]
  • [Cites] Hum Mutat. 1994;3(2):121-5 [8199592.001]
  • [Cites] J Clin Pathol. 1994 Sep;47(9):860-1 [7962661.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] AJR Am J Roentgenol. 1995 Dec;165(6):1460-1 [7484586.001]
  • [Cites] Int J Colorectal Dis. 1996;11(2):88-91 [8739833.001]
  • [Cites] Lancet. 1996 Aug 17;348(9025):433-5 [8709782.001]
  • [Cites] Int J Colorectal Dis. 1996;11(4):157-62 [8876270.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2400-10 [8941012.001]
  • [Cites] Br J Surg. 1996 Nov;83(11):1494-504 [9014661.001]
  • [Cites] Gut. 1996 Dec;39(6):867-9 [9038672.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] Chirurgie. 1997;122(1):31-4 [9183898.001]
  • [Cites] World J Surg. 1998 Dec;22(12):1231-6 [9841749.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1007-14 [9869223.001]
  • [Cites] J Med Genet. 1999 Jan;36(1):65-7 [9950370.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):350-61 [10077047.001]
  • [Cites] Dis Colon Rectum. 1999 Apr;42(4):529-32 [10215057.001]
  • [Cites] Am J Pathol. 1999 Jul;155(1):7-9 [10393829.001]
  • [Cites] Br J Surg. 1999 Sep;86(9):1185-9 [10504375.001]
  • [Cites] Am J Hum Genet. 1952 Mar;4(1):31-6 [14933371.001]
  • [Cites] Am J Hum Genet. 1953 Jun;5(2):139-47 [13065261.001]
  • [Cites] Dis Colon Rectum. 1959 Sep-Oct;2:465-8 [13839882.001]
  • [Cites] J Clin Pathol. 2005 Jan;58(1):97-101 [15623495.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1642-54 [15887156.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):273-80 [15947102.001]
  • [Cites] Fam Cancer. 2005;4(2):135-8 [15951964.001]
  • [Cites] Lancet. 2005 Jun 11-17;365(9476):2014-23 [15950715.001]
  • [Cites] J Pediatr. 2005 Aug;147(2):263-6 [16126064.001]
  • [Cites] Ned Tijdschr Tandheelkd. 2005 Sep;112(9):340-4 [16184913.001]
  • [Cites] Arch Pathol Lab Med. 2005 Nov;129(11):1398-400 [16253018.001]
  • [Cites] Pancreas. 2005 Nov;31(4):428-9 [16258383.001]
  • [Cites] Radiology. 2005 Dec;237(3):794-800 [16304103.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):385-98 [16454848.001]
  • [Cites] Gastrointest Endosc. 2006 Apr;63(4):570-80 [16564854.001]
  • [Cites] Thyroid. 2006 Feb;16(2):109-42 [16420177.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Pediatr Blood Cancer. 2006 Nov;47(6):851-4 [16106429.001]
  • [Cites] Pediatr Blood Cancer. 2006 Nov;47(6):811-8 [16317745.001]
  • [Cites] Fam Cancer. 2006;5(3):263-73 [16998672.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1258-64 [16952208.001]
  • [Cites] Horm Res. 2006;66(5):207-10 [16865001.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jun;103(6):e30-4 [17449294.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Feb;6(2):215-9 [18237870.001]
  • [CommentIn] Ann Surg Oncol. 2009 May;16(5):1446-8; author reply 1449-50 [19266242.001]
  • (PMID = 18612695.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein
  • [Number-of-references] 111
  • [Other-IDs] NLM/ PMC2518080
  •  go-up   go-down


68. Castillo OA, Vitagliano G, Kerkebe M, Parma P, Pinto I, Diaz M: Laparoscopic adrenalectomy for suspected metastasis of adrenal glands: our experience. Urology; 2007 Apr;69(4):637-41
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 34 adrenalectomies were performed in 32 patients for incidental adrenal masses discovered at primary tumor diagnosis or during follow-up.
  • The primary tumors diagnosed were 13 cases of lung carcinoma, 9 of renal cell carcinoma, 2 of colorectal carcinoma, 2 of bladder carcinoma, and 1 each of ovarian carcinoma, breast cancer, gastric cancer, and melanoma.
  • Two patients had no history of a primary tumor.
  • The mean tumor size was 4.3 cm (range 1.5 to 9).
  • The microscopic analysis revealed 22 malign lesions (64.7%) and 12 cases of benign pathologic features (35.3%).
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Laparoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17445640.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Uner A, Ebinc FA, Akyurek N, Unsal D, Mentes BB, Dursun A: Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol; 2005 Sep;27(3):225-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma.
  • AIM: To analyze vascular endothelial growth factor (VEGF), c-erbB-2 and c-erbB-3 expression and to evaluate their relation to clinicopathologic parameters and pathogenesis of colorectal carcinoma.
  • METHODS: Sections of adenoma, intramucosal carcinoma and adenocarcinoma were evaluated by immunohistochemistry in 85 malignant and 37 benign colorectal neoplasms for the expression of VEGF, c-erbB-2 and c-erbB-3 considering clinicopathological variables.
  • RESULTS: VEGF was detected in comparable percentages of all neoplasm types while c-erbB-2 expression was detectable more frequently in adenoma than adenocarcinoma cases (65% vs 43%).
  • Except for the correlation of c-erbB-3 expression with Dukes' staging, there was no correlation between the studied markers and grade of differentiation, Dukes' stage and localization of colorectal adenocarcinoma. c-erbB-3 expression was seen more frequently in tubular adenomas, while c-erbB-2 expression was higher in tubulovillous and villous types.
  • CONCLUSION: These results suggest that VEGF, c-erbB-2, c-erbB-3 expression does not have prognostic value in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Colorectal Neoplasms / genetics. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-3 / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Profiling. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244586.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3
  •  go-up   go-down


70. Tsafrir D, Bacolod M, Selvanayagam Z, Tsafrir I, Shia J, Zeng Z, Liu H, Krier C, Stengel RF, Barany F, Gerald WL, Paty PB, Domany E, Notterman DA: Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res; 2006 Feb 15;66(4):2129-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of gene expression and chromosomal abnormalities in colorectal cancer.
  • In this work, three types of array-generated data (expression, single nucleotide polymorphism, and comparative genomic hybridization) were collected from a large set of colon cancer patients at various stages of the disease.
  • We show that across many large regions of the genome, changes in expression level are correlated with alterations in DNA content.
  • Often, large chromosomal segments, containing multiple genes, are transcriptionally affected in a coordinated way, and we show that the underlying mechanism is a corresponding change in DNA content.
  • Indeed, particular chromosomal regions are frequently gained and overexpressed (e.g., 7p, 8q, 13q, and 20q) or lost and underexpressed (e.g., 1p, 4, 5q, 8p, 14q, 15q, and 18) in primary colon tumors, making it likely that these changes favor tumorigenicity.
  • Furthermore, we show that these aberrations are absent in normal colon mucosa, appear in benign adenomas (albeit only in a small fraction of the samples), become more frequent as disease advances, and are found in the majority of metastatic samples.
  • [MeSH-major] Chromosome Aberrations. Colorectal Neoplasms / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Chromosomes, Human, Pair 20 / genetics. DNA, Neoplasm / genetics. Gene Dosage. Gene Expression Profiling. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16489013.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA65930
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


71. Kupka S, Haack B, Zdichavsky M, Mlinar T, Kienzle C, Bock T, Kandolf R, Kroeber SM, Königsrainer A: Large proportion of low frequency microsatellite-instability and loss of heterozygosity in pheochromocytoma and endocrine tumors detected with an extended marker panel. J Cancer Res Clin Oncol; 2008 Apr;134(4):463-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large proportion of low frequency microsatellite-instability and loss of heterozygosity in pheochromocytoma and endocrine tumors detected with an extended marker panel.
  • PURPOSE: Pheochromocytoma (PCC) is a usually benign tumor originated in the majority of patients from the adrenal medulla.
  • Since microsatellite markers used for MSI detection have only been recommended for colorectal carcinoma (CRC), we established an extended marker set for MSI detection in PCC.
  • Our marker set comprised the reference panel for CRC and six additional markers, which have already been described to detect MSI in tumors other than CRC.
  • Moreover, 23 endocrine tumors with gastrointestinal origin were examined in order to test the applicability of this marker panel.
  • Among the 23 patients with endocrine tumors, only three (one pancreatic endocrine tumor, one duodenal neuro-endocrine tumor, one hepatic metastasis of a primary tumor with unknown origin) demonstrated MSI.
  • [MeSH-major] Endocrine Gland Neoplasms / genetics. Loss of Heterozygosity. Microsatellite Instability. Microsatellite Repeats. Pheochromocytoma / genetics
  • [MeSH-minor] Adult. Aged. Colorectal Neoplasms / genetics. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Teratog Carcinog Mutagen. 2003;Suppl 1:255-65 [12616616.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):241-9 [15944796.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):353-60 [11433399.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3444-9 [11705861.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):229-36 [15599934.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1564-7 [15619218.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):38-44 [8536886.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):285-92 [11196176.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(20):2347-54 [12351569.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):93-8 [17143284.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1114-5 [17021141.001]
  • [Cites] Hum Mol Genet. 1998 May;7(5):895-903 [9536095.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] In Vivo. 2005 Mar-Apr;19(2):359-65 [15796198.001]
  • [Cites] Hum Pathol. 2002 Mar;33(3):322-9 [11979373.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2536-40 [12171881.001]
  • [Cites] Int J Colorectal Dis. 2006 Oct;21(7):625-31 [16557375.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):10-1 [17192781.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):300-3 [9521327.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Apr 15;150(2):128-35 [15066320.001]
  • [Cites] World J Surg. 2006 Jul;30(7):1240-6 [16715450.001]
  • [Cites] Exp Mol Med. 2004 Apr 30;36(2):122-9 [15150440.001]
  • [Cites] Breast Cancer Res Treat. 2000 Mar;60(2):135-42 [10845276.001]
  • [Cites] Surgery. 2003 Dec;134(6):902-8; discussion 909 [14668721.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Cancer Treat Rev. 2006 Dec;32(8):607-18 [17055172.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):145-52 [16724208.001]
  • (PMID = 17828419.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


72. Uenoyama Y, Seno H, Fukuda A, Sekikawa A, Nanakin A, Sawabu T, Kawada M, Kanda N, Suzuki K, Yada N, Fukui H, Chiba T: Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway. Oncogene; 2006 Jun 1;25(23):3277-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway.
  • Cyclooxygenase-2 (COX-2) plays important roles in tumor development.
  • Especially in the early-stage colorectal tumors, COX-2 expression is often observed in the tumor stroma.
  • In the present study, we simulated the indirect interaction between epithelial cells and stromal cells in the process of colorectal tumor development using an in vitro co-culture model in which NIH3T3 fibroblasts were co-cultured with 'sparsely' or 'densely' populated intestinal epithelial cells, Intestine-407 as a model of premalignant or benign intestinal epithelial cells, and DLD-1 and Caco-2 as models of malignant epithelial cells.
  • Interestingly, there was pericellular hypoxia in the vicinity of NIH3T3 fibroblasts when co-cultured with 'dense' epithelial cells, and the recovery of the partial pressure of oxygen level resulted in the reduction of enhanced COX-2 expression only in NIH3T3 fibroblasts co-cultured with 'dense' Intestine-407 cells.
  • Thus, pericellular hypoxia of the stromal cells caused by densely populated epithelial cells may be one of the potent COX-2 enhancers before completion of malignant transformation during intestinal tumor development.
  • [MeSH-minor] Animals. Caco-2 Cells. Cell Count. Cell Line, Tumor. Coculture Techniques. Enzyme Induction / physiology. Humans. Mice. NIH 3T3 Cells. Precancerous Conditions / enzymology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Stromal Cells / enzymology. Stromal Cells / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16407821.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Transcription Factor AP-1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


73. Metser U, You J, McSweeney S, Freeman M, Hendler A: Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. AJR Am J Roentgenol; 2010 Mar;194(3):766-71
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
  • OBJECTIVE: The purpose of this study was to compare FDG PET/CT and contrast-enhanced 64-MDCT of the chest, abdomen, and pelvis in the detection of tumor recurrence in patients with colorectal cancer and an elevated level of carcinoembryonic antigen (CEA).
  • MATERIALS AND METHODS: A retrospective analysis included 50 patients (31 men, 19 women; mean age, 61 years; range, 28-89 years) with 55 clinical events of elevated or increasing CEA level who underwent FDG PET/CT and MDCT for suspected tumor recurrence.
  • Fifty-four of 61 tumor sites suspected as tumor recurrence with any imaging technique were found to be local recurrence or metastatic colorectal cancer at final analysis.
  • The other seven sites were one separate malignant tumor (small lymphocytic lymphoma) and six benign lesions.
  • Diagnosis was based on histopathologic findings (n = 27) or clinical and imaging findings (n = 35) during a median follow-up period of 12 months (range, 6-31 months).
  • One site of tumor recurrence was missed prospectively at both MDCT and PET/CT.
  • In a tumor site-based analysis, the sensitivities of PET/CT and MDCT were 98.1% and 66.7% (p < 0.0001), and the specificities were 75% and 62.5% (p = 0.56).
  • Tumors correctly identified with PET/CT and missed with MDCT were local recurrence in the presacral space (n = 5), metastatic subcentimeter lymph nodes (n = 4), peritoneal deposits (n = 3), and recurrences at the periphery of radiofrequency ablated metastatic lesions of the liver (n = 2) and in the abdominal wall (n = 1), liver (n = 1), and uterine cervix (n = 1).
  • CONCLUSION: FDG PET/CT has higher sensitivity than MDCT in the identification of sites of recurrent and metastatic disease in patients with colorectal cancer and an elevated CEA level.
  • [MeSH-major] Colorectal Neoplasms / radiography. Colorectal Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoembryonic Antigen / blood. Contrast Media. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / radiography. Neoplasm Metastasis / radionuclide imaging. Radiographic Image Interpretation, Computer-Assisted. Radiography, Abdominal. Radiography, Thoracic. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173157.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


74. Agaba AE, Berry N, Agaba PO, Charaklias N, Wong LS: One stop rectal bleeding clinic: the coventry experience. Int Surg; 2006 Sep-Oct;91(5):288-90
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In most patients, the cause is attributed to a benign lesion.
  • Left-sided tumors account for the majority of these tumors and are within the reach of a flexible sigmoidoscopy.
  • Patients were asked of the nature of rectal bleed and altered bowel habits and were examined by digital rectal examination, with a proctoscopy and rigid sigmoidoscopy before either a full colonoscopic examination or flexible sigmoidoscopy with a completion Barium enema.
  • During the study period, colorectal cancer was detected in 4 patients (1.6%), adenomatous polyps in 36 patients (14.4%), and ulcerative colitis in 8 patients (3.2%).
  • [MeSH-major] Gastrointestinal Hemorrhage / diagnosis. Gastrointestinal Hemorrhage / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17061675.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


75. Singhi AD, Montgomery EA: Colorectal granular cell tumor: a clinicopathologic study of 26 cases. Am J Surg Pathol; 2010 Aug;34(8):1186-92
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal granular cell tumor: a clinicopathologic study of 26 cases.
  • Granular cell tumor (GCT) is commonly located in the subcutaneous tissue and oral cavity, and uncommon in the gastrointestinal tract, in which the majority arises in the esophagus with over-representation in African Americans (AA).
  • We report the clinicopathologic features of 1 of the largest series to date of colorectal GCTs.
  • We reviewed the clinical features of 26 colorectal GCTs seen at our institution between the years 1995 to 2009, which included 24 biopsies, 1 low anterior resection, and 1 colectomy.
  • The majority of colorectal GCT involved the right colon (19/26, 73%) ranging in size from 0.2 to 1.8 cm (mean 0.6 cm).
  • Most neoplasms were encountered on routine colonoscopy (14/24, 64%), however 3 patients presented with hematochezia, 3 with changing bowel habits, 2 with Crohn disease, 1 with diverticular disease, and 1 with appendicitis.
  • Of the 20 cases available for histologic review, the tumors were noted to either be infiltrative (12/20, 60%) or marginated (8/20, 40%) involving either the mucosa (7/20, 35%), submucosa (10/20, 50%), or both (3/20, 15%).
  • The microscopic features were similar to those of GCTs found elsewhere, but many of the neoplasms differed by displaying nuclear pleomorphism (8/20, 40%), lymphoid cuffs (9/20, 45%), and focal calcification (7/20, 35%).
  • On immunochemistry, 18 of the neoplasms were stained for S-100 and all cases showed positive staining.
  • Although infrequently found in the colorectum, colorectal GCT typically presents incidentally on routine colonoscopy and involves the right colon; it is not over-represented in AA patients.
  • GCTs can have both an infiltrative or marginated growth pattern with a subset displaying nuclear pleomorphism, a lymphoid cuff, focal calcification, and reactive mucosal surface changes, which in our experience, may lead to misdiagnosis on colorectal mucosal biopsies.
  • Although GCTs were benign tumors in this series, if incompletely excised regrowth of the lesion may occur and therefore, follow-up may be warranted.
  • [MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biopsy. Colectomy. Colonoscopy. Female. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. S100 Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661017.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


76. Pickhardt PJ, Kim DH, Meiners RJ, Wyatt KS, Hanson ME, Barlow DS, Cullen PA, Remtulla RA, Cash BD: Colorectal and extracolonic cancers detected at screening CT colonography in 10,286 asymptomatic adults. Radiology; 2010 Apr;255(1):83-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal and extracolonic cancers detected at screening CT colonography in 10,286 asymptomatic adults.
  • PURPOSE: To retrospectively determine the detection rates, clinical stages, and short-term patient survival for all unsuspected cancers identified at screening computed tomographic (CT) colonography, including both colorectal carcinoma (CRC) and extracolonic malignancies.
  • MATERIALS AND METHODS: From April 2004 through March 2008, prospective colorectal and extracolonic interpretation was performed in 10,286 outpatient adults (5388 men, 4898 women; mean age, 59.8 years) undergoing screening CT colonography at two centers in this institutional review board-approved, HIPAA-compliant study.
  • Benign neoplasms (including advanced colorectal adenomas), symptomatic lesions, and tumors without pathologic proof were excluded.
  • Extracolonic malignancies included renal cell carcinoma (n = 11), lung cancer (n = 8), non-Hodgkin lymphoma (n = 6), and a variety of other tumors (n = 11).
  • [MeSH-major] Colonography, Computed Tomographic. Colorectal Neoplasms / diagnostic imaging
  • [MeSH-minor] Adenoma / diagnostic imaging. Adenoma / pathology. Female. Humans. Kidney Neoplasms / diagnostic imaging. Kidney Neoplasms / pathology. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / pathology. Lymphatic Metastasis. Lymphoma, Non-Hodgkin / diagnostic imaging. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neoplasms, Multiple Primary / diagnostic imaging. Neoplasms, Multiple Primary / pathology. Radiographic Image Interpretation, Computer-Assisted. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2010
  • (PMID = 20308446.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA144835
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


77. Issakov J, Jiveliouk I, Nachmany I, Klausner J, Merimsky O: A histopathological review of gastrointestinal related mesenchymal tumors: the hidden GIST. Isr Med Assoc J; 2007 Nov;9(11):810-2
Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A histopathological review of gastrointestinal related mesenchymal tumors: the hidden GIST.
  • BACKGROUND: The diagnosis of gastrointestinal stromal tumors is based on documentation of c-KIT and platelet-derived growth factor-alpha receptors or specific c-KIT mutations.
  • Before the diagnosis of GIST was possible, all cases had been classified as sarcomas or benign tumors.
  • OBJECTIVES: To identify cases of GIST formerly diagnosed as abdominal or retroperitoneal mesenchymal tumors.
  • METHODS: We reviewed the archive material on all surgical cases diagnosed as gastrointestinal related malignant mesenchymal tumors or GIST in our medical center during the last decade (1995-2004).
  • Thirty-eight were reconfirmed to be GIST, 19 were newly diagnosed as GIST (the hidden cases), 8 cases were re-diagnosed as mesenchymal tumors, and 3 cases of sarcoma remained sarcomas.
  • Of all the GIST tumors, c-KIT-positive and PDGFRalpha-positive tumors were more characteristic of primary gastric tumors, while c-KIT-positive and PDGFRalpha-negative tumors were found in the colorectal area.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18085040.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


78. Jeong WK, Park JW, Choi HS, Chang HJ, Jeong SY: Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center. Surg Endosc; 2009 Nov;23(11):2575-9
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center.
  • BACKGROUND: Transanal endoscopic microsurgery (TEM) is a minimally invasive alternative to transanal excision, enabling complete local excision of selected benign or malignant rectal tumors.
  • This study aimed to determine the surgical and oncologic results for rectal tumors excised by TEM.
  • METHODS: From November 2001 to October 2007, 45 patients underwent TEM for excision of adenoma (13 patients), carcinoid tumor (6 patients), and carcinoma (26 patients).
  • RESULTS: The median tumor distance from the anal verge was 7 cm (range, 3-15 cm), and the median tumor size was 17 mm (range, 2-60 mm).
  • No recurrence occurred for six patients with carcinoid tumors.
  • Histologic examination of the carcinomas showed pathologic tumor (pT) stage 0 (ypT0) in 2 patients, pT1 in 17 patients (including ypT1 in 1 patient), pT2 in 6 patients, and pT3 in 1 patient.
  • CONCLUSIONS: The TEM procedure is a safe and appropriate surgical treatment option for benign rectal tumors.
  • [MeSH-major] Anal Canal / surgery. Microsurgery / methods. Neoplasm Recurrence, Local / pathology. Proctoscopy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Cancer Care Facilities. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Korea. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Patient Selection. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2001 Sep;234(3):352-8; discussion 358-9 [11524588.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):207-10 [8689164.001]
  • [Cites] Chirurg. 1984 Oct;55(10):677-80 [6510078.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1167-72 [15154642.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):880-5 [1914721.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1003-8 [2754446.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):97-102 [17111281.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Am J Surg. 2007 Nov;194(5):694-8 [17936438.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):547-56 [16514476.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1026-30; discussion 1030-1 [18481147.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1546-52 [16252312.001]
  • [Cites] Dis Colon Rectum. 1996 Aug;39(8):886-92 [8756844.001]
  • [Cites] Am J Clin Oncol. 1994 Oct;17(5):411-6 [8092113.001]
  • [Cites] Colorectal Dis. 2004 Sep;6(5):350-5 [15335369.001]
  • [Cites] World J Surg. 1992 May-Jun;16(3):437-46 [1317077.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):989-95 [12163970.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1106-11 [14597451.001]
  • [Cites] Surg Endosc. 2007 Jun;21(6):970-4 [17285371.001]
  • [Cites] Br J Surg. 2007 May;94(5):627-33 [17335125.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):969-76 [8797643.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] Arch Surg. 1998 Jun;133(6):595-8; discussion 598-9 [9637456.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):581-5 [16919110.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):270-84 [15711865.001]
  • (PMID = 19347399.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


79. Holten-Andersen MN, Hansen U, Brünner N, Nielsen HJ, Illemann M, Nielsen BS: Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int J Cancer; 2005 Jan 10;113(2):198-206
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma.
  • We have previously demonstrated that TIMP-1 is elevated in blood from colorectal cancer patients and that high TIMP-1 levels predict poor prognosis.
  • To clarify the role of TIMP-1 in colorectal tumorigenesis, the expression pattern of TIMP-1 in benign and malignant colorectal tumors was studied.
  • In all of 24 cases of colorectal adenocarcinoma TIMP-1 mRNA was detected by in situ hybridization.
  • No TIMP-1 mRNA was seen in any of the cases in benign or malignant epithelial cells, in vascular cells or smooth muscle cells.
  • In conclusion, TIMP-1 expression is a rare event in benign human colon tissue but is highly expressed by myofibroblasts in association with invading colon cancer cells.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenoma / genetics. Adenoma / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Tissue Inhibitor of Metalloproteinase-1 / biosynthesis. Tissue Inhibitor of Metalloproteinase-1 / pharmacology
  • [MeSH-minor] Case-Control Studies. Cell Transformation, Neoplastic. Diagnosis, Differential. Fibroblasts / physiology. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Neoplasm Invasiveness. RNA, Messenger / analysis. RNA, Messenger / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15386409.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1
  •  go-up   go-down


80. Braendle W, Kuhl H, Mueck A, Birkhäuser M, Thaler C, Kiesel L, Neulen J: [Does hormonal contraception increase the risk for tumors?]. Ther Umsch; 2009 Feb;66(2):129-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Does hormonal contraception increase the risk for tumors?].
  • A non-contraceptive benefit of oral hormonal contraceptives (OC) is a diminished risk for certain benign as well as malignant tumours, such as benign breast tumours, uterine fibroids and ovarian cysts.
  • Long-term use of OC leads to a decreased risk of endometrial and colorectal carcinomata.
  • [MeSH-major] Contraceptives, Oral, Hormonal / adverse effects. Neoplasms / chemically induced
  • [MeSH-minor] Adult. Age Factors. Case-Control Studies. Female. Genital Neoplasms, Female / chemically induced. Genital Neoplasms, Female / genetics. Humans. Long-Term Care. Middle Aged. Risk Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180433.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Hormonal
  • [Number-of-references] 47
  •  go-up   go-down


81. Koukoutsis I, Pappas A, Karanikas G, Kotzadimitriou K, Chrysikos J, Tzika S, Koronakis N, Karavitis G, Lagoudianakis E, Manouras A: Desmoid tumor of the supraclavicular region: a case report. Cases J; 2009;2:7222

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoid tumor of the supraclavicular region: a case report.
  • Desmoid tumors are rare, benign fibroblastic tumors that are locally infiltrative and can cause extensive morbidity by destruction of adjacent vital structures.
  • Due to the rarity of these tumors, evidence regarding optimal treatment protocols is drawn from case reports and single-arm series with small patient numbers.
  • We report a case of a patient with a desmoid tumor of the left supraclavicular region that was diagnosed and treated in our department and a review of the current literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1390-7 [12663732.001]
  • [Cites] Am J Surg Pathol. 1977 Sep;1(3):255-70 [920873.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1517-23 [10738207.001]
  • [Cites] J Surg Oncol. 2008 May 1;97(6):554-8 [18425778.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4642-60 [17008706.001]
  • [Cites] Orthop Clin North Am. 2006 Jan;37(1):53-63 [16311111.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):158-67 [10458229.001]
  • [Cites] Am J Clin Oncol. 1998 Dec;21(6):584-90 [9856660.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):637-45 [9486614.001]
  • [Cites] Br J Surg. 1996 Nov;83(11):1494-504 [9014661.001]
  • [Cites] Int J Colorectal Dis. 1996;11(4):157-62 [8876270.001]
  • [Cites] Arch Surg. 1989 Feb;124(2):191-6 [2916941.001]
  • [Cites] J Bone Joint Surg Am. 1984 Dec;66(9):1369-74 [6501332.001]
  • [Cites] Am J Clin Pathol. 1982 Jun;77(6):665-73 [7091046.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):181-90 [12562642.001]
  • (PMID = 19829936.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2740207
  •  go-up   go-down


82. Halazun KJ, Al-Mukhtar A, Aldouri A, Malik HZ, Attia MS, Prasad KR, Toogood GJ, Lodge JP: Right hepatic trisectionectomy for hepatobiliary diseases: results and an appraisal of its current role. Ann Surg; 2007 Dec;246(6):1065-74
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 275 patients, 160 had colorectal metastases, 49 had biliary tract cancers, 20 had hepatocellular carcinomas, 20 had other metastatic tumors, and 12 had benign diseases.
  • Concomitant procedures were carried out in 192 patients: caudate lobectomy in 45 patients, resection of tumors from the liver remnant in 57 patients, resection of the extrahepatic biliary tree in 45 patients, and lymphadenectomy in 45 patients.
  • Survivals for individual tumor types were acceptable, with 5-year survivals for colorectal metastasis and cholangiocarcinoma being 38% and 32%, respectively.
  • The outcome is not influenced by additional concomitant resection of tumors from the planned liver remnant.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2008 Jul;248(1):138-9; author reply 139-40 [18580219.001]
  • (PMID = 18043112.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Baatrup G, Elbrønd H, Hesselfeldt P, Wille-Jørgensen P, Møller P, Breum B, Qvist N: Rectal adenocarcinoma and transanal endoscopic microsurgery. Diagnostic challenges, indications and short term results in 142 consecutive patients. Int J Colorectal Dis; 2007 Nov;22(11):1347-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 43%of the patients, the cancer diagnosis was not recognized before TEM.
  • Eighty-five percent of all tumors were classified as benign based on macroscopic appearance; on digital rectal examination, 35% were benign, rectal ultrasound classified 15% as benign, and the preoperative biopsy was benign in 36%.
  • CONCLUSION: All larger rectal tumors should be evaluated for malignancy before treatment, even if TEM is the only surgical option, due to high age and comorbidiy.
  • When resecting large sessile tumors, there is a considerable risk of incomplete radicality.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Microsurgery / methods. Proctoscopy / methods. Rectal Neoplasms / diagnosis. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol Suppl. 2003;(239):34-9 [14743881.001]
  • [Cites] Chirurg. 1984 Oct;55(10):677-80 [6510078.001]
  • [Cites] Eur J Surg Oncol. 1986 Dec;12(4):373-7 [3780991.001]
  • [Cites] Gut. 1984 May;25(5):437-44 [6714785.001]
  • [Cites] Dig Surg. 2005;22(3):182-9; discussion 189-90 [16137996.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):974-80 [12905551.001]
  • [Cites] Colorectal Dis. 2004 May;6(3):153-7 [15109377.001]
  • [Cites] Abdom Imaging. 2003 Nov-Dec;28(6):784-93 [14753591.001]
  • [Cites] BMJ. 2003 Nov 22;327(7425):1196-201 [14630754.001]
  • [Cites] Colorectal Dis. 2002 Nov;4(6):467-72 [12790922.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):200-6 [11852333.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1380-8 [15906120.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Dec;19(6):993-1005 [16338654.001]
  • [Cites] Colorectal Dis. 2000 Sep;2(5):252-63 [23578114.001]
  • (PMID = 17643251.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


84. Liu W, Wei W, Winer D, Bamberger AM, Bamberger C, Wagener C, Ezzat S, Asa SL: CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene; 2007 Apr 26;26(19):2747-58
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CEACAM1 is a putative tumor suppressor based on diminished expression in some solid neoplasms such as colorectal carcinoma.
  • However, CEACAM1 is overexpressed in some tumors such as non-small cell lung cancer.
  • CEACAM1 is expressed in thyroid carcinoma cell lines derived from tumors that exhibit aggressive behavior.
  • Forced CEACAM1 expression enhanced cell-matrix adhesion and migration and promoted tumor invasiveness.
  • Conversely, small interfering RNA (siRNA)-mediated downregulation of CEACAM1 expression in MRO cells accelerated cell cycle progression and significantly enhanced tumor size in xenografted mice.
  • CEACAM1 is not appreciably expressed in normal thyroid tissue or benign thyroid tumors.
  • In a human thyroid tissue array, CEACAM1 reactivity was associated with metastatic spread but not with increased tumor size.
  • These findings identify CEACAM1 as a unique mediator that restricts tumor growth whereas increasing metastatic potential.
  • [MeSH-major] Antigens, CD / physiology. Carcinoembryonic Antigen / metabolism. Cell Adhesion Molecules / physiology. Cell Proliferation. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adult. Aged. Animals. Carcinoma / metabolism. Carcinoma / pathology. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / genetics. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Female. Gene Expression Regulation, Neoplastic. Gene Silencing. Humans. Male. Mice. Mice, SCID. Middle Aged. Neoplasm Invasiveness. RNA, Small Interfering / pharmacology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17057731.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / CDKN1A protein, human; 0 / Carcinoembryonic Antigen; 0 / Ceacam1 protein, mouse; 0 / Cell Adhesion Molecules; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / RNA, Small Interfering; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


85. He Q, Zhang P, Zou L, Li H, Wang X, Zhou S, Fornander T, Skog S: Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep; 2005 Oct;14(4):1013-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
  • Activity of thymidine kinase 1 in serum (STK) is a useful marker for leukaemia and lymphoma, but not for solid tumors.
  • We investigate thymidine kinase 1 concentration in serum (S-TK1) as a potential tumor marker.
  • S-TK1 concentration and STK activity levels were determined in 9 human malignant diseases (breast, gastric, rectal, colorectal, lung, brain cancer, hepatoma, lymphoma, leukaemia) and in benign and non-cancerous diseases, representing 850 preoperative cases.
  • S-TK1 concentrations and STK activity levels in preoperative malignant patients were significantly higher than in healthy individuals, in patients with benign tumors and in those with non-cancerous diseases.
  • Significant correlations between concentration and activity level were only found in healthy individuals, in patients with benign tumors, and in some patients with malignancies, i.e. leukaemia, and breast and gastric cancers.
  • We conclude that S-TK1 concentration is a more sensitive tumor marker in solid malignancies than is STK activity.
  • [MeSH-major] Biomarkers, Tumor. Neoplasms / blood. Neoplasms / diagnosis. Thymidine Kinase / blood
  • [MeSH-minor] Breast Neoplasms / pathology. Cell Line, Tumor. Cell Proliferation. Dose-Response Relationship, Drug. Female. Humans. Male. Neoplasm Staging. Radioimmunoassay / methods. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142366.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.21 / Thymidine Kinase; EC 2.7.1.21 / thymidine kinase 1
  •  go-up   go-down


86. Uchiyama K, Ueno M, Ozawa S, Kiriyama S, Shigekawa Y, Yamaue H: Combined use of contrast-enhanced intraoperative ultrasonography and a fluorescence navigation system for identifying hepatic metastases. World J Surg; 2010 Dec;34(12):2953-9
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The purpose of this study was to assess the concomitant use of contrast-enhanced intraoperative ultrasound (CE-IOUS) using the new microbubble agent Sonazoid, and to assess the fluorescence navigation system (Photo Dynamic Eye, or PDE) using indocyanine green (ICG) as a novel tool for identifying colorectal metastatic lesions compared with preoperative contrast-enhanced multiple row-detected computed tomography (MDCT) and gadoxetic acid-enhanced MRI.
  • METHODS: Thirty-two patients who underwent a liver resection for colorectal metastatic carcinoma from 2008 to 2009 were included in the present study.
  • RESULTS: A total of 56 lesions were identified based on the histopathological findings of the biopsies and resected tissues; of these, 52 were confirmed to be metastases, whereas 4 were benign tumors.
  • [MeSH-major] Colorectal Neoplasms / pathology. Contrast Media. Fluorescent Dyes. Liver Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. INDOCYANINE GREEN .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Surg. 2009 Oct;35(10 ):1495-8 [19674039.001]
  • [Cites] AJR Am J Roentgenol. 2009 Jun;192(6):1675-81 [19457834.001]
  • [Cites] AJR Am J Roentgenol. 2009 Jan;192(1):180-7 [19098199.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):236-40 [16432357.001]
  • [Cites] World J Gastroenterol. 2007 Feb 28;13(8):1252-6 [17451209.001]
  • [Cites] J Ultrasound Med. 2009 Sep;28(9):1133-42 [19710210.001]
  • [Cites] J Surg Oncol. 2009 Jul 1;100(1):75-9 [19301311.001]
  • [Cites] Ann Surg Oncol. 2010 Jan;17(1):144-51 [19774415.001]
  • [Cites] J Ultrasound Med. 2009 Apr;28(4):439-48 [19321671.001]
  • [Cites] Jpn J Radiol. 2009 May;27(4):185-93 [19499310.001]
  • [Cites] Dig Surg. 2009;26(5):392-9 [19923827.001]
  • [Cites] Cancer. 2009 Jun 1;115(11):2491-504 [19326450.001]
  • [Cites] World J Surg. 2008 Aug;32(8):1763-7 [18543027.001]
  • [Cites] World J Gastroenterol. 2008 May 28;14 (20):3207-11 [18506927.001]
  • [Cites] Br J Surg. 2009 Nov;96(11):1289-94 [19847873.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14 (4):1347-55 [17253105.001]
  • [Cites] Dig Dis. 2009;27(2):114-24 [19546549.001]
  • (PMID = 20734045.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Ferric Compounds; 0 / Fluorescent Dyes; 0 / Oxides; 0 / Sonazoid; 0 / gadolinium ethoxybenzyl DTPA; E1UOL152H7 / Iron; IX6J1063HV / Indocyanine Green; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


87. Tamura H, Ohtsuka M, Washiro M, Kimura F, Shimizu H, Yoshidome H, Kato A, Seki N, Miyazaki M: Reg IV expression and clinicopathologic features of gallbladder carcinoma. Hum Pathol; 2009 Dec;40(12):1686-92
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regenerating islet-derived family, member 4 (Reg IV) has been shown to be associated with colorectal carcinogenesis and gastric carcinogenesis through intestinal metaplasia.
  • Before surgical resection, 4 (33%) of 12 patients with gallbladder carcinoma had high serum Reg IV levels, whereas Reg IV was never elevated in 12 patients with benign diseases.
  • The serum levels of Reg IV decreased after surgical resection of the tumors.
  • The serum level of Reg IV may be of use or indicative of neoplasia.
  • [MeSH-major] Adenocarcinoma / metabolism. Gallbladder Neoplasms / metabolism. Lectins, C-Type / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Enzyme-Linked Immunosorbent Assay. Gene Expression. Homeodomain Proteins / biosynthesis. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Metaplasia / genetics. Metaplasia / metabolism. Metaplasia / pathology. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716164.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Lectins, C-Type; 0 / REG4 protein, human
  •  go-up   go-down


88. Cherqui D, Laurent A, Tayar C, Karoui M: [Laparoscopic hepatectomy]. Bull Acad Natl Med; 2007 Nov;191(8):1661-81; discussion 1681-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The indications were benign in 65 cases (40%) and malignant in 94 cases (60%).
  • The most frequent benign disorders were symptomatic hepatocyte tumors and tumors of uncertain nature (adenomas and focal nodular hyperplasia in 40 cases).
  • The malignant lesions comprised 60 cases of hepatocellular carcinoma on a cirrhotic liver and 20 metastases of colorectal cancer.
  • The tumors had a diameter of 44 mm (range 4-170 mm).
  • The mean resection margin for malignant tumors was 14 mm and there were no relapses on the trocar ports.
  • [MeSH-minor] Female. Humans. Liver Neoplasms / surgery. Male. Surgical Instruments

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18666465.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


89. Robles R, Marín C, Fernández JA, Ramírez P, Sánchez-Bueno F, Morales D, Luján JA, Abellán B, Ramírez M, Cascales P, Pérez D, Parrilla P: [Toward zero mortality in liver resection. Presentation of 200 consecutive cases]. Cir Esp; 2005 Jul;78(1):19-27
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common indication was liver metastases in 123 patients (61.5%), primary malignant liver tumors in 27 patients (13.5%), bile duct tumors in 27 patients (13.5%) and benign disease in 23 patients (11.5%).
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Carcinoma. Liver Neoplasms
  • [MeSH-minor] Colorectal Neoplasms / mortality. Colorectal Neoplasms / secondary. Colorectal Neoplasms / surgery. Female. Humans. Male. Middle Aged. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cir Esp. 2005 Dec;78(6):392 [16420871.001]
  • [CommentIn] Cir Esp. 2005 Jul;78(1):1-2 [16420783.001]
  • (PMID = 16420786.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Spain
  •  go-up   go-down


90. Agaimy A, Wünsch PH: Gastrointestinal stromal tumours: a regular origin in the muscularis propria, but an extremely diverse gross presentation. A review of 200 cases to critically re-evaluate the concept of so-called extra-gastrointestinal stromal tumours. Langenbecks Arch Surg; 2006 Aug;391(4):322-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM AND METHODS: To study the diversity of gross presentation of GISTs and to critically assess the incidence of EGISTs and their relationship to mural GISTs, a total of 200 neoplasms with typical morphologic and immunohistochemical features of GISTs were reviewed, looking for any degree of association with the muscularis propria of the gut wall.
  • RESULTS: There were 130 gastric (65%), 9 duodenal (4.5%), 48 small intestinal (24%), 9 colorectal (4.5%), 1 appendiceal (0.5%) and 3 unclassifiable GISTs (1.5%).
  • After critical re-evaluation of surgical reports and remote clinical history and a careful search for residual muscular tissue from the gut wall in the tumour pseudocapsule (in some cases supported by desmin immunoreactivity), it was possible to reclassify most of these cases (11/14) as either GISTs with extensive extramural growth resulting in loss of contact to the external muscle coat of the gut (8/14) or as metastases from an inoperable GIST (2/14) or from a previously resected deceptively benign tumour (1/14).
  • In contrast to most other neoplasms, GISTs should be defined by virtue of any degree of association with the muscularis propria (no matter how minimal), but not by localisation of the bulk of the tumour.
  • [MeSH-major] Gastrointestinal Neoplasms / surgery. Gastrointestinal Stromal Tumors / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Gastrointestinal Tract / pathology. Humans. Male. Middle Aged. Muscle, Smooth / pathology. Pelvic Neoplasms / diagnosis. Pelvic Neoplasms / pathology. Pelvic Neoplasms / surgery. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2001 Jun;32(6):578-82 [11431711.001]
  • [Cites] Virchows Arch. 2001 Jan;438(1):1-12 [11213830.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):326-7 [10680913.001]
  • [Cites] Gastroenterology. 1991 May;100(5 Pt 1):1417-31 [2013387.001]
  • [Cites] Z Gastroenterol. 2004 Mar;42(3):233-42 [15022111.001]
  • [Cites] Surg Today. 2004;34(2):159-62 [14745619.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Apr;19(4):467-70 [15012791.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 2001 Sep;92(6):624-7 [11593705.001]
  • [Cites] Chirurg. 2004 Jul;75(7):708-12 [15257404.001]
  • [Cites] J Korean Med Sci. 2004 Oct;19(5):763-7 [15483360.001]
  • [Cites] J Laryngol Otol. 2004 Apr;118(4):315-6 [15117476.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):894-7 [10835530.001]
  • [Cites] Histopathology. 2004 Jan;44(1):77-80 [14717673.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Dec;22(6):1014-6 [12467832.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1420-3 [11023105.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):630-5 [14675690.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Histopathology. 2003 May;42(5):511-3 [12713631.001]
  • [Cites] Dig Dis Sci. 2002 Jul;47(7):1492-7 [12141805.001]
  • [Cites] Int J Urol. 2004 Jun;11(6):445-7 [15157221.001]
  • [Cites] Arch Pathol Lab Med. 2003 Dec;127(12):1606-8 [14632569.001]
  • [Cites] Am J Clin Pathol. 2003 Mar;119(3):339-45 [12645334.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Virchows Arch. 2005 Apr;446(4):470-2 [15756592.001]
  • [Cites] Arch Pathol Lab Med. 2004 Dec;128(12):1442-4 [15578893.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] J Reprod Med. 2003 Aug;48(8):655-8 [12971151.001]
  • [Cites] Pathol Int. 2001 Jul;51(7):524-31 [11472565.001]
  • [Cites] Histopathology. 2001 May;38(5):387-402 [11422475.001]
  • [Cites] Can J Surg. 2004 Feb;47(1):70 [14997931.001]
  • [Cites] Tumori. 1997 May-Jun;83(3):703-8 [9267492.001]
  • [Cites] Int J Gynecol Cancer. 2004 Mar-Apr;14 (2):373-7 [15086741.001]
  • [Cites] J Med Invest. 2002 Aug;49(3-4):186-92 [12323009.001]
  • [Cites] Mod Pathol. 2000 May;13(5):577-85 [10824931.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1134-42 [11048809.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1157-63 [10751339.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):889-94 [15223958.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):947-57 [10895817.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):660-7 [12949711.001]
  • [Cites] Arch Pathol Lab Med. 1990 May;114(5):522-5 [1692203.001]
  • [Cites] J Mol Diagn. 2004 Aug;6(3):197-204 [15269295.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1109-18 [10478672.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):377-89 [10199467.001]
  • [Cites] J Urol. 2001 Jan;165(1):185 [11125397.001]
  • (PMID = 16402273.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


91. Bezsilla J, Bende S, Varga L, Botos A, Liptay-Wagner P, Sikorszki L, Sümegi J, Nagy G: [Laparoscopic colon operations for endoscopically unremovable polyps and tumors]. Magy Seb; 2005 Oct;58(5):305-10
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic colon operations for endoscopically unremovable polyps and tumors].
  • The use of laparoscopy in colorectal surgery is expanding.
  • Minimally invasive surgery of benign lesions is widely accepted and can be performed with good results even during the learning curve.
  • On one occasion a benign polyp was removed through mini laparotomy after colotomy; 13 resections and 2 subtotal colectomies were performed.
  • [MeSH-major] Colectomy / methods. Colonic Neoplasms / surgery. Colonic Polyps / surgery. Laparoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16496772.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


92. Zhang W, Hart J, McLeod HL, Wang HL: Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms. Am J Clin Pathol; 2005 Jul;124(1):11-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms.
  • We immunohistochemically examined 75 human colorectal neoplasms (adenoma, 27; adenocarcinoma, 24; neuroendocrine carcinoma, 24) for the expression of activator protein (AP)-1 family proteins.
  • Nuclear and cytoplasmic expression levels of c-Jun and Fra-1 proteins were markedly elevated in adenomas, adenocarcinomas and neuroendocrine carcinomas compared with nonneoplastic colorectal epithelial cells.
  • JunB also was overexpressed in these tumors but with a predominantly cytoplasmic staining pattern.
  • Expression levels of JunD and c-Fos were high in nonneoplastic colorectal epithelial cells and remained so in neoplasms.
  • FosB was undetectable in nonneoplastic and neoplastic colorectal tissues.
  • Hierarchical clustering separated the majority of malignant from benign tumors based on AP-1 expression patterns.
  • AP-1 transcription factor family members are expressed differentially in nonneoplastic and neoplastic colorectal tissues.
  • Up-regulation of c-Jun and Fra-1 is an early event in human colorectal tumorigenesis.
  • Overexpression of Fra-2 may participate in tumor progression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Neuroendocrine / metabolism. Colorectal Neoplasms / metabolism. Epithelial Cells / metabolism. Transcription Factor AP-1 / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923159.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM63340
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-fos; 0 / Proto-Oncogene Proteins c-jun; 0 / Transcription Factor AP-1; 0 / fos-related antigen 1
  •  go-up   go-down


93. Brosseuk D, Oosthuizen J, Pinchbeck M: Initial experience with a general population colorectal cancer screening clinic. Am J Surg; 2006 May;191(5):669-72
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial experience with a general population colorectal cancer screening clinic.
  • BACKGROUND: Recognition of adenoma to carcinoma progression has established colorectal cancer as a preventable malignancy.
  • Colorectal cancer is, therefore, an ideal malignancy for preventative screening given the presence of a benign precursor.
  • METHODS: A retrospective chart review of all patients referred to a new low-risk colorectal cancer endoscopic screening clinic from October 1, 2004 to September 30, 2005 was performed.
  • Those patients found to have adenomas or carcinomas were analyzed further regarding location of neoplasm and pathologic findings.
  • RESULTS: A total of 379 low-risk patients attended the colorectal cancer screening clinics.
  • Of the 67 patients with neoplasms, 50 were left of the splenic flexure, 11 were right of the splenic flexure, and 5 patients had lesions both proximal and distal to the flexure.
  • Thirty-two of the 67 patients had complete colonoscopy at the initial procedure and, thus far, 21 patients have had completion colonoscopies, of which 9 patients had further neoplasms identified beyond the splenic flexure.
  • All 3 patients with carcinoma had early tumors resected with curative intent, with negative margins and negative nodes.
  • CONCLUSIONS: Our initial experience with a low-risk general population colorectal cancer endoscopic screening clinic yielded 18% of patients with neoplasms, and 1% had curable cancers resected.
  • [MeSH-major] Cancer Care Facilities. Colonoscopy. Colorectal Neoplasms / diagnosis. Mass Screening / methods
  • [MeSH-minor] Aged. Aged, 80 and over. British Columbia / epidemiology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors. Video Recording

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647357.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Wang W, Feng B, Li X, Yin P, Gao P, Zhao X, Lu X, Zheng M, Xu G: Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry. Mol Biosyst; 2010 Oct;6(10):1947-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry.
  • Colorectal carcinoma (CRC) is the third most commonly encountered cancer and fourth cause of cancer-associated death worldwide.
  • In this study both ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) and online affinity solid phase extraction-high performance liquid chromatography (SPE-HPLC) were used to analyze the urinary metabolites from 34 healthy volunteers, 34 benign colorectal tumor and 50 colorectal carcinoma patients to produce comprehensive metabolic profiling data.
  • [MeSH-major] Chromatography, High Pressure Liquid / methods. Colorectal Neoplasms / urine. Mass Spectrometry / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20617254.001).
  • [ISSN] 1742-2051
  • [Journal-full-title] Molecular bioSystems
  • [ISO-abbreviation] Mol Biosyst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


95. Piccolo SR, Frey LJ: Somatic mutation signatures of cancer. AMIA Annu Symp Proc; 2008 Nov 06;:202-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The advancement of cancer diagnosis, prognosis, and treatment would be hastened via a robust method to identify patterns that indicate a tumor's state.
  • Prior research has established that sporadic, colorectal-cancer pathogenesis involves a series of genetic mutations that allow benign polyps to develop and eventually progress to malignant tumors in distinguishable patterns.
  • Our results for colorectal cancer are consistent with what extant biological models as described in the literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Pharmacogenomics. 2007 Dec;8(12):1629-33 [18085994.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):318-22 [16421597.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D354-7 [16381885.001]
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):1387-95 [1347643.001]
  • [Cites] N Engl J Med. 2008 Jan 31;358(5):502-11 [18234754.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):769-80 [15510158.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):197-205 [14993901.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):8685-90 [17502601.001]
  • [Cites] Bioinformatics. 2007 Oct 1;23(19):2507-17 [17720704.001]
  • (PMID = 18999255.001).
  • [ISSN] 1942-597X
  • [Journal-full-title] AMIA ... Annual Symposium proceedings. AMIA Symposium
  • [ISO-abbreviation] AMIA Annu Symp Proc
  • [Language] ENG
  • [Grant] United States / NLM NIH HHS / LM / T15 LM007124; United States / NLM NIH HHS / LM / 1T15-LM007124
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2655983
  •  go-up   go-down


96. Oh SJ, Lee SJ, Lee HY, Paik YH, Lee DK, Lee KS, Chung JB, Yu JS, Yoon DS: [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas]. Korean J Gastroenterol; 2009 Sep;54(3):162-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas].
  • BACKGROUND/AIMS: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has a favorable prognosis, but seems to be associated with a high incidence of extrapancreatic tumors.
  • The purpose of this study was to evaluate the incidence and clinicopathological features of extrapancreatic tumors associated with IPMN.
  • These patients were examined for the development of extrapancreatic tumors.
  • RESULTS: Of 37 patients with IPMN, 14 (38%) had 18 extrapancreatic tumors, and 10 (27%) had 13 extrapancreatic malignancies.
  • Five, six, and two extrapancreatic malignancies had been diagnosed before, during, and after the diagnosis of IPMN.
  • Gastric adenocarcinoma (3 patients, 23%) and colorectal carcinoma (3 patients, 23%) were the most common neoplasms.
  • Other extrapancreatic tumors included lung cancer (n=2), prostatic cancer (n=1), renal cell carcinoma (n=1), cholangiocellular carcinoma (n=1), urinary bladder cancer (n=1), and gallbladder cancer (n=1), respectively.
  • As benign tumor, there were two gallbladder adenoma, one gastric adenoma, one colonic adenoma and one benign ovarian cystic neoplasm, respectively.
  • CONCLUSIONS: IPMN is associated with high incidence of extrapancreatic tumors, particularly gastric and colorectal neoplasms.
  • Upper gastrointestinal endoscopy and colonoscopy should be done, and systemic surveillance for the possible occurrence of other tumors may allow early detection of extrapancreatic tumor in patients with IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasms, Multiple Primary / epidemiology. Neoplasms, Second Primary / epidemiology. Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2009 Sep;54(3):196-8 [19844158.001]
  • (PMID = 19844152.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


97. Levin TG, Powell AE, Davies PS, Silk AD, Dismuke AD, Anderson EC, Swain JR, Wong MH: Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. Gastroenterology; 2010 Dec;139(6):2072-2082.e5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: CD166 (also called activated leukocyte cell adhesion molecule [ALCAM]) is a marker of colorectal cancer (CRC) stem cells; it is expressed by aggressive tumors.
  • Although the presence of CD166 at the tumor cell surface has been correlated with shortened survival, little is known about its function and expression in normal intestinal epithelia.
  • Human and mouse intestinal tumors were also analyzed.
  • RESULTS: CD166 was expressed on the surface of epithelial cells within the stem cell niche and along the length of the intestine; expression was conserved across species.
  • In the small intestine, CD166 was observed on crypt-based Paneth cells and intervening crypt-based columnar cells (putative stem cells).
  • CD166 was located in the cytoplasm and at the surface of cells within human CRC tumors.
  • CD166-positive cells were also detected in benign adenomas in mice; rare cells coexpressed CD166 and CD44 or epithelial-specific antigen.
  • CD166-positive cells appear at multiple stages of intestinal carcinoma progression, including benign and metastatic tumors.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Exp Med. 1995 Jun 1;181(6):2213-20 [7760007.001]
  • [Cites] Differentiation. 2003 Jan;71(1):28-41 [12558601.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):805-13 [9502422.001]
  • [Cites] J Bone Miner Res. 1998 Apr;13(4):655-63 [9556065.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):895-902 [14737120.001]
  • [Cites] Eur J Immunol. 2004 Apr;34(4):930-40 [15048703.001]
  • [Cites] J Clin Pathol. 2004 Nov;57(11):1160-4 [15509676.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Exp Cell Res. 1992 Nov;203(1):91-9 [1426054.001]
  • [Cites] J Biol Chem. 1993 Aug 25;268(24):18345-58 [8349710.001]
  • [Cites] J Neurobiol. 1994 Jul;25(7):831-45 [8089660.001]
  • [Cites] J Exp Med. 1995 Apr 1;181(4):1563-8 [7535342.001]
  • [Cites] J Cell Biol. 1998 May 4;141(3):765-77 [9566975.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55315-23 [15496415.001]
  • [Cites] J Cell Sci. 2005 Apr 1;118(Pt 7):1515-25 [15769845.001]
  • [Cites] Oncology. 2005;68(4-6):462-70 [16024937.001]
  • [Cites] Nature. 2006 Jan 5;439(7072):84-8 [16397499.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):403-9 [16484444.001]
  • [Cites] FEBS Lett. 2006 May 15;580(11):2637-45 [16650408.001]
  • [Cites] J Immunol. 2006 Jul 15;177(2):877-84 [16818742.001]
  • [Cites] Med Sci Monit. 2006 Aug;12(8):BR263-73 [16865058.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):102-7 [17143262.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Development. 2007 Apr;134(8):1491-7 [17344225.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 [17548814.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2737-46 [17938267.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] Science. 2008 Jan 18;319(5861):336-9 [18202291.001]
  • [Cites] Nat Immunol. 2008 Feb;9(2):137-45 [18157132.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10(3):353-60 [18264089.001]
  • [Cites] Stem Cells. 2008 Mar;26(3):630-7 [18055444.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1726-33 [18347173.001]
  • [Cites] Cell Death Differ. 2008 Jun;15(6):947-58 [18259194.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):48-53 [18356041.001]
  • [Cites] PLoS One. 2008;3(6):e2428 [18560594.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):915-20 [18536716.001]
  • [Cites] BMC Gastroenterol. 2008;8:57 [19055726.001]
  • [Cites] Cell. 2009 Mar 6;136(5):903-12 [19269367.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3382-9 [19336570.001]
  • [Cites] Cell Stem Cell. 2009 May 8;4(5):427-39 [19427292.001]
  • [Cites] Nature. 2009 May 14;459(7244):262-5 [19329995.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2010 May;298(5):G590-600 [20185687.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):769-74 [10702391.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(3-4):I-XI, 193-383 [11394186.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2134-42 [11568000.001]
  • [Cites] J Exp Med. 2002 Jun 17;195(12):1549-63 [12070283.001]
  • [Cites] Prostate. 2003 Jan 1;54(1):34-43 [12481253.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2706-16 [9108388.001]
  • (PMID = 20826154.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118235; United States / NIDDK NIH HHS / DK / U01 DK085525-02; United States / NHLBI NIH HHS / HL / T32 HL007781; United States / NCI NIH HHS / CA / CA106195-06A1; United States / NCI NIH HHS / CA / CA118235-05; United States / NICHD NIH HHS / HD / T32 HD049309-05; United States / NCI NIH HHS / CA / CA106195; United States / NCI NIH HHS / CA / T32 CA106195; United States / NICHD NIH HHS / HD / HD049309; United States / NICHD NIH HHS / HD / T32 HD049309; United States / NCI NIH HHS / CA / T32 CA106195-06A1; United States / NHLBI NIH HHS / HL / T32 HL007781-14; United States / NIDDK NIH HHS / DK / R01 DK068326; United States / NCI NIH HHS / CA / CA118235; United States / NIDDK NIH HHS / DK / R01 DK068326-05; United States / NIDDK NIH HHS / DK / DK068326; United States / NIDDK NIH HHS / DK / DK085525-02; United States / NICHD NIH HHS / HD / HD049309-05; United States / NHLBI NIH HHS / HL / HL007781-14; United States / NHLBI NIH HHS / HL / HL007781; United States / NIDDK NIH HHS / DK / U01 DK085525; United States / NIDDK NIH HHS / DK / DK085525; United States / NIDDK NIH HHS / DK / DK068326-05; United States / NCI NIH HHS / CA / R01 CA118235-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ALCAM protein, human; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules, Neuronal; 0 / Fetal Proteins
  • [Other-IDs] NLM/ NIHMS234467; NLM/ PMC2997177
  •  go-up   go-down


98. Lind GE, Ahlquist T, Kolberg M, Berg M, Eknaes M, Alonso MA, Kallioniemi A, Meling GI, Skotheim RI, Rognum TO, Thiis-Evensen E, Lothe RA: Hypermethylated MAL gene - a silent marker of early colon tumorigenesis. J Transl Med; 2008;6:13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Tumor-derived aberrantly methylated DNA might serve as diagnostic biomarkers for cancer, but so far, few such markers have been identified.
  • The aim of the present study was to investigate the potential of the MAL (T-cell differentiation protein) gene as an early epigenetic diagnostic marker for colorectal tumors.
  • METHODS: Using methylation-specific polymerase chain reaction (MSP) the promoter methylation status of MAL was analyzed in 218 samples, including normal mucosa (n = 44), colorectal adenomas (n = 63), carcinomas (n = 65), and various cancer cell lines (n = 46).
  • Immunohistochemical analysis of MAL was done using normal colon mucosa samples (n = 5) and a tissue microarray with 292 colorectal tumors.
  • RESULTS: Bisulphite sequencing revealed that the methylation was unequally distributed within the MAL promoter and by MSP analysis a region close to the transcription start point was shown to be hypermethylated in the majority of colorectal carcinomas (49/61, 80%) as well as in adenomas (45/63, 71%).
  • CONCLUSION: Promoter hypermethylation of MAL was present in the vast majority of benign and malignant colorectal tumors, and only rarely in normal mucosa, which makes it suitable as a diagnostic marker for early colorectal tumorigenesis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / genetics. DNA Methylation. Membrane Transport Proteins / genetics. Myelin Proteins / genetics. Proteolipids / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 May 29;22(22):3463-71 [12776198.001]
  • [Cites] J Histochem Cytochem. 2003 May;51(5):665-74 [12704214.001]
  • [Cites] J Obstet Gynaecol Res. 2004 Feb;30(1):53-8 [14718022.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):475-80 [1911187.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3455-60 [9699680.001]
  • [Cites] J Cell Biol. 1999 Apr 5;145(1):141-51 [10189374.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2029-33 [10232580.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3730-40 [10446989.001]
  • [Cites] Gastroenterology. 2005 Jan;128(1):192-206 [15633136.001]
  • [Cites] Neoplasia. 2005 Feb;7(2):99-108 [15802015.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):797-808 [16952549.001]
  • [Cites] Cell Oncol. 2006;28(5-6):259-72 [17167179.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jan;5(1):111-7 [17161655.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632 [17408629.001]
  • [Cites] Dis Colon Rectum. 2007 Oct;50(10):1618-26; discussion 1626-7 [17762966.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):808-11 [9041175.001]
  • [Cites] DNA Cell Biol. 1997 Mar;16(3):245-55 [9115633.001]
  • [Cites] Endocrinology. 1998 Apr;139(4):2077-84 [9528996.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6870-5 [9618505.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4366-71 [10969779.001]
  • [Cites] Lab Invest. 2001 Feb;81(2):217-29 [11232644.001]
  • [Cites] Nucleic Acids Res. 2001 Jul 1;29(13):E65-5 [11433041.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):574-9 [11870540.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):820-9 [12610180.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1747-57 [14652236.001]
  • (PMID = 18346269.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MAL protein, human; 0 / Membrane Transport Proteins; 0 / Myelin Proteins; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / Proteolipids
  • [Other-IDs] NLM/ PMC2292685
  •  go-up   go-down


99. Adler A, Roll S, Marowski B, Drossel R, Rehs HU, Willich SN, Riese J, Wiedenmann B, Rösch T, Berlin Private-Practice Gastroenterology Working Group: Appropriateness of colonoscopy in the era of colorectal cancer screening: a prospective, multicenter study in a private-practice setting (Berlin Colonoscopy Project 1, BECOP 1). Dis Colon Rectum; 2007 Oct;50(10):1628-38
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appropriateness of colonoscopy in the era of colorectal cancer screening: a prospective, multicenter study in a private-practice setting (Berlin Colonoscopy Project 1, BECOP 1).
  • In the diagnostic group, indications were assessed according to the current guidelines for appropriateness (American Society for Gastrointestinal Endoscopy, European Panel for the Appropriateness of Gastrointestinal Endoscopy), and the results were correlated with the percentage of relevant findings (tumors, inflammatory conditions).
  • However, the percentage of relevant inflammatory and neoplastic findings (polyps, cancer, inflammatory bowel disease, benign strictures) was only 5 to 10 percent higher in the appropriate group than in the inappropriate group.
  • [MeSH-major] Colonoscopy / utilization. Colorectal Neoplasms / diagnosis. Mass Screening / utilization. Private Practice / statistics & numerical data


100. Kupcsulik P: [Laparoscopic colorectal surgery]. Magy Seb; 2006 Apr;59(2):79-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic colorectal surgery].
  • Laparoscopic surgery have earned a firm place in the treatment of benign colon diseases.
  • Concerning the treatment of malignant colorectal tumors the value of LAP surgery has evoked controversial assessments.
  • On the basis of onco-surgical guidelines for colorectal carcinoma conventional standards began to sway.
  • Independent factors like tumor stage, R0 resection, histological parameters and surgeon determine prognosis.
  • Previous discussions about port site metastases and tumor cell dissemination by pneumoperitoneum have silenced.
  • Several randomized studies have proven the short term superiority of LAP resection in term of postoperative pain management, bowel movement, hospital stay and rehabilitation over open methods.
  • Newly, more multicentric randomized trials were conducted on late results of LAP surgery for malignant colorectal tumors which has been proved nonsignificantly better or equal to conventional surgery.
  • Based on the above mentioned data laparoscopic colorectal surgery became an accepted option for treatment of colorectal carcinoma.
  • [MeSH-major] Colorectal Surgery. Laparoscopy
  • [MeSH-minor] Colonic Diseases / surgery. Colorectal Neoplasms / surgery. Humans. Prognosis. Quality of Life. Randomized Controlled Trials as Topic. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784030.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 88
  •  go-up   go-down






Advertisement